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LIST OF ABBREVIATIONS  
BNP= Brain Natriuretic Peptide  
CH= Concentric Hypertrophy 
EH= Eccentric Hypertrophy 
CR= Concentric Remodelling 
DALYs= Disability Life Years 
EDD=End Diastolic Diameter  
ESD= End Systolic Diameter  
HT= Hypertension without LVH or heart failure 
HHF=Hypertensive Heart Failure 
HTLVH= Hypertension with LVH but no heart failure 
IVSDd= Interventricular Septal Diameter at end diastole 
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RAA= Right Atrial Area 
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LVF=Left Ventricular Failure  
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LVM=Left Ventricular Mass 
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MA= Atrial Filling of the Left Ventricle 
NT= N- Terminal  
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1 Abstract  
There is substantial evidence that the burden of hypertension, hypertension with left 
ventricular hypertrophy and hypertensive heart failure is very enormous in sub-Saharan 
Africa. There is therefore the need to look for easier and faster means, compared to 
electrocardiography and echocardiography of diagnosing and differentiating the different 
effects of long standing hypertension on cardiac remodelling which ultimately lead to 
systolic and diastolic dysfunctions as this affects the prognosis, management and 
treatment modalities of hypertension. We studied 210 subjects who were subdivided into 
three groups after echocardiography: those without left ventricular hypertrophy (HT) 
(n=83); those with left ventricular hypertrophy (HTLVH) (n=50) and those with 
hypertensive heart failure (HHF) (n=77). The subjects had a mean age of 
52.3±11.3years, and the female subjects constituted 42.4% of the study population. 
HTLVH had the highest levels of mean arterial blood pressure and pulse pressure 
among the cohort of 120.6±26.7mmHg and 67.0±26.9mmHg respectively.   
HTLVH had both significantly higher inter-ventricular and left ventricular posterior wall 
hypertrophy thickness when compared with HT and HHF subjects, p-values<0.001 
respectively, while Subjects with HHF had the highest chamber diameters apart from the 
right atrial area. Subjects with HHF had higher plasma ST2 concentrations compared to 
HTLVH (134.7pg/ml±57.3ng/ml versus 23.0ng/ml±8.3pg/ml, p-value<0.0001) and those 
with HT (134.7±57.3 versus 14.5±4.9, p-value<0.0000).NT-pro BNP levels were similar 
when HTLVH was compared with HT (p=0.68), but subjects with HHF had significantly 
higher NT-pro BNP compared to HTLVH (p<0.0002) and HT (p<0.0001). Also on head-
to-head comparison using differences in areas under the curve, ST2 was found to be a 
better biomarker than NT-pro BNP in differentiating HT from HHF (p<0.0001) and 
HTLVH from HHF (p=0.01). Serum ST2 is a powerful biomarker in differentiating the 
different spectrum of hypertension. It does not only complement the role of NT-pro BNP 














CHAPTER 1  
1.0 Introduction 
Hypertension or high blood pressure is a very important worldwide public health problem 
because of its high rate of occurrence and concomitant risk of cardiovascular, 
cerebrovascular and kidney disease (He et al 1997; Whelton 1994). Hypertension has 
been identified as the leading risk factor for mortality. In the latest global burden of 
disease survey (Lim et al  2012), hypertension is ranked as the leading risk factor for 
poor health in 2010, as against the fourth leading risk factor for poor health in 1990 
(Figure 1.1:Five Leading Risk Factors for Poor Health in 1990 and 2010; Adapted from 
GBD Project 2010). 
The importance of high blood pressure as a major cause of common serious disease 
has been recognised in most Western countries for over 50 years (Harrington M et al 
1959). Before this, malignant hypertension was a frequent reason for hospital admission 
and a common cause of death. Safe and effective anti–hypertensive drugs were first 
developed in the 1960s and were shown to dramatically improve the prognosis 
associated with malignant hypertension (Yu et al 1960). Subsequently, the provision of 
blood pressure lowering treatments to a much broader group of patients at risk of 
serious cardiovascular diseases, such as cerebrovascular accident and coronary heart 
disease, importantly contributed to the decline in stroke and coronary heart disease 
death rates experienced by most Western populations (Unal  et al 2005). However, in 
contrast to higher-income countries, the burden of hypertension and hypertension–
related diseases increased in lower–income countries. This has been attributed to 





















Figure 1.1: The main causes of global DALYs and top five risk factors for poor 
health in 1990 and 2010(adapted from GBD Project 2010) 
1.1  Definition of Hypertension 
The cut-off mark for the definition of hypertension has evolved over time. The current 
definition is that of the Seventh Joint National Committee Report (JNC7) which defines 
three levels of elevated blood pressure (Chobanian et al 2003). These are: stage 1 
hypertension which is defined as systolic blood pressure (SBP) between 140 – 
159mmHg and/or diastolic blood pressure between 90 -99mmHg.  Stage 2 hypertension 
on the other hand refers to all levels of systolic blood pressure greater or equal to 
160mmHg and/or diastolic blood pressure greater or equal to 100mmHg. JNC7 also 
introduced the classification of blood pressure between 120mmHg to 139mmHg systolic 
blood pressure or 80 to 89mmHg diastolic blood pressure as pre-hypertension, based on 
the risk of progression and associated cardiovascular risk. Patients with blood pressure 
in the 130/80mmHg to 139/989 mmHg range have been found to be at twice the risk of 















1.2  Worldwide Prevalence of Hypertension  
The World Health Organisation (WHO) estimated that a quarter of the world’s adult 
population (totalling nearly one billion) had hypertension in 2000. It is predicted to 
increase to 1.56 billion in 2025, and it has also been suggested that men and women 
have similar overall prevalence of hypertension worldwide and that such prevalence 
consistently increases with age in all regions.  
Sample national surveys for hypertension conducted in the 1990s (survey sizes ranged 
from 1800 – 23100) were identified in Germany, Finland, Sweden, England, Spain, Italy, 
Canada and the United States. The different prevalence, according to country, is: Italy: 
37.7%, Sweden: 38.4%, England: 41.7%, Spain: 46.8%, Finland: 48.7%, Germany: 
55.3%, United States: 27.8% and Canada: 27.4%. The prevalence of hypertension for 
the European average was 44.2%, while that for the whole of North America was 27%. 
(Katharina et al 2003). In these surveys, age-specific hypertension prevalence increased 
similarly to systolic blood pressure for individual countries, with a higher intercept and 
slightly higher slope in Europe, compared to Canada and the United States. For 
example, the prevalence in the age group 35-44 years was 14% in the North American 
countries and 27% in Europe, and this increased to 53% and 78% respectively, among 
patients aged 65-74 years.  
In cross-sectional surveys of hypertension in four rural and urban communities in sub-
Saharan Africa, the age-standardized prevalence of hypertension was 19.3% in rural 
Nigeria, 21.4% in rural Kenya, 23.7% in urban Tanzania and 38.0% in urban Namibia 
(Marleen et al 2012).  
In a systematic review of 25 studies (> 400 subjects each) from 10 sub-Saharan African 
Countries namely: Nigeria, Tanzania, South Africa, Ghana, Sudan, Cameroun, Liberia, 
Eritrea, Senegal and Gambia, prevalence of hypertension ranged from 13 – 48% with 
rural to urban gradient (Addo  et al 2007). The rural, semi-urban and urban prevalence 
of hypertension in some regions of sub-Saharan Africa are shown in figure 1.2. 
 
1.3  Prevalence of Hypertension in Nigeria 
In Nigeria the crude prevalence of hypertension has been documented to be 11.2% 
(based on blood pressure threshold of 160/95 monthly) with an age–adjusted rate of 
9.3% (Akinkugbe 1997). However, with the current definition of high blood pressure, 












and Treatment of High Blood Pressure (JNC VII) guidelines, 20 – 25% of adult Nigerians 
are said to be hypertensive (Ogah 2006). In a meta-analysis of nine community-based 
studies in Nigeria between 1990 and 2009, the prevalence of hypertension ranged from 
a minimum of 12.4% to 34.8% and combined prevalence rate was 22%, with 95% 
confidence interval of 17-27%. In the same meta-analysis, the pooled prevalence of 

































































(13 Rural, 2 Semi-Urban, 3 Rural/ 




5 studies identified 










Figure 1.2: Map of Africa Showing Prevalence of Hypertension in some 
regions 
 
1.4     Hypertension and Target Organ Damage  
Hypertension is a major risk factor for cardiovascular disease. It is also a leading cause 
of cerebrovascular accident, chronic kidney disease and heart failure. (Minino et al 
2011). Recent publications have shown that systolic blood pressure (SBP) values are 
more predictive of cardiovascular disease than diastolic blood pressure values (Benetos 
et al 2002). It has also been found that each 20mmHg increase in SBP over the range of 
115 – 185 mmHg doubles coronary heart disease and stroke mortality (Lewington et al 
2002). In addition, hypertension has also been found to be a causal factor in at least 












about half the life time stroke risk of those with hypertension (Bronner et al 1995; Wolf et 
al 1991). 
 
Furthermore, a relatively small decrease in systolic blood pressure (as low as 10 mmHg) 
has been shown to be associated with a 25% - 30% lower fatal stroke rate (Staessen et 
al 2001) and the incidence of end-stage renal disease has  been found to increase in 
parallel with systolic blood pressure. When normal systolic blood pressure of less than 
120mmHg is compared with a systolic blood pressure of 140-159mmHg, the relative risk 
of end–stage renal disease is increased three-fold and for systolic blood pressure of 160 
– 179 mmHg, end-stage renal disease risk increases six-fold (Klag et al 1996). In the 
report of the Prospective Trialists’ Group, each 20/10mmHg increase in blood pressure 
doubles the risk of  ischaemic heart disease and cerebrovascular accident over the  
range of 115/75 to 185/115 mmHg in individuals from 40 – 90 years age. The slope of 
the relationship between hypertension and cerebrovascular disease is about twice as 
steep as the comparable slope of the cholesterol–CVD relationship (Lewington et al 
2002; Joint National Committee on Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure 1997). One of the main manifestations of hypertension’s end–
organ effects especially in the black population is hypertensive heart disease which is a 
spectrum of abnormalities that represent the accumulation of structural and functional 
adaptations to increased blood pressure load. Features of this syndrome include left 
ventricular hypertrophy, increasing vascular and ventricular stiffness and diastolic 





























Adapted from: Arch Intern Med 1996; 156:1926-1935.  
     Figure 1.3: Complications of Hypertension (Adapted from Dutsan et al. 1996) 
 
1.5 Hypertension and Left Ventricular Hypertrophy 
LVH is defined as left ventricular wall thickness and/or mass and is the best studied 
marker of hypertensive heart disease (Mensah et al 1994). Increased left ventricular wall 
thickness and mass have continuously been found to be associated with the level of 
blood pressure and age. However, without increased systolic blood pressure, clinically 
significant increases in left ventricular mass do not occur with advancing age. Chronic 
systolic hypertension therefore eems to be the principal cause of left ventricular 
hypertrophy (Levy et al 1988; Rheeder et al 1999). LVH serves as an integrated 
surrogate for cumulated blood pressure load and is best described as being proportional 
to the area under the lifetime BP curve. This is also supported by the fact that there is a 
strong association of left ventricular mass and mean 24-hour ambulatory blood pressure 
(Wendelin–Saarehovi et al 2002; Mancia et al 1997) 
Other factors, apart from hypertension and age, that have been linked to left ventricular 
wall hypertrophy include race (with healthy young blacks having greater left ventricular 
wall thickness compared to white population), sex, salt intake, insulin and Insulin Growth 
Factor-I(IGF-I), obesity, high alcoholic intake, plasma viscosity, physical activity and 
genetics (Akinyemi et al 2009; Hinderliter et al 1992) 













Prevalence of Hypertensive Left Ventricular Hypertrophy 
In general, echocardiographically determined left ventricular wall hypertrophy ranges 
from about 20 – 60% in hypertensive individuals. As with other forms of target organ 
damage, hypertensive left ventricular wall hypertrophy is more prevalent in African-
Americans (Post et al 2003). Most studies show higher left ventricular wall thickness in 
African–Americans than in white hypertensive subjects (Houghton JL et al., 1997; 
Chaturvedi et al 1984; Gottdiener et al 1994; Gardin et al 1995; Koren et al 1993).  
In Ibadan, South-West Nigeria (Aje A et al 2006), LVH was found in 20.8% of the 
uncontrolled hypertensive group and 24.1% of the controlled hypertensive group when 
left ventricular mass was indexed to body surface area. However, when left ventricular 
mass was indexed to height, left ventricular hypertrophy was found in 22.4% of 
uncontrolled hypertensive subjects and 24.1% of controlled hypertensive subjects. In 
another study conducted in Ibadan (Salako et al 2009), when 100 newly presenting 
hypertensives were compared with 100 normal controls, only 28% of the hypertensive 
subjects had normal left ventricular geometric pattern, compared to 86% of the normal 
controls. 
 
1.6 Classification of Left Ventricular Hypertrophy 
Left ventricular geometric pattern has been classified into four types, based on left 
ventricular mass index (LVMI) and relative wall thickness (the ratio of wall thickness to 
cavity diameter). This is shown in figure 1.4: Diagramatic Representation of the Four Left 
Ventricular Geometric Patterns. Some of these hypertensive patients may develop 
concentric hypertrophy and others eccentric hypertrophy. Some factors that have been 
implicated on the geometric pattern developed include the joint influences of volume 
overload, pressure overload and contractile dysfunction (Ganau et al 1990; Ganau et al 
1992; Devereux et al 1994). It has also been shown that some of the apparent variability 
of the hypertrophic response among hypertensive patients is attributable to the severity, 
duration or rate of increase of the blood pressure (Ross et al 1997). Patients with 
concentric versus eccentric hypertrophy have been shown to have higher systolic blood 
pressures and total peripheral resistance (Ganau et al 1992). In addition, ambulatory 
blood pressure has been found to be a better correlate of left ventricular mass than 
single office blood pressure measurements (Fagard et al 1997). For example, subjects 












ambulatory blood pressure, even when the office blood pressure was not dramatically 
different between the two groups (Devereux et al 1993). 
Demographic factors have also been shown to modulate the manner in which the left 
ventricle responds to an elevation in blood pressure. For example, black subjects 
compared with whites appear to be predisposed to concentric hypertrophy (Kizer et al 
2004; Draznes et al 2005). In subjects with isolated systolic hypertension, women were 
more likely to develop concentric left ventricular hypertrophy and men more likely to 
develop eccentric hypertrophy (Krumholz et al 1993). Increasing age has also been 
associated with concentric, as opposed to eccentric hypertrophy, in hypertensive 
subjects assessed by echocardiography (Chahal et al 2010) 
Combined factors like diabetes, mellitus, obesity and coronary artery disease can also 
affect the pattern of hypertrophic response. In the Losartan Intervention for End Point 
Reduction in Hypertension Study, coronary artery disease was associated with an 
increased left ventricular diastolic dimension and a higher prevalence of eccentric left 
ventricular hypertrophy (Zabalgoitia et al 2001). Diabetes mellitus has been associated 
with a concentric hypertrophic response (Palmieri et al 2001). Obesity on the other hand, 
which is characterised by volume-overload state, is associated predominantly with 
eccentric hypertrophy (Gottdiener et al 1994; de Simone et al 1994). Another factor 
which influences the development of either concentric or eccentric hypertrophy in 
hypertensive subjects is variation in neuro-hormonal activation. For example, differences 
in plasma rennin activity are widespread in hypertensive subjects. Some investigators 
have shown that high- versus low–rennin states lead to concentric hypertrophy (Davila 
et al 2008), while subjects with eccentric hypertrophy have been shown to have low 
plasma rennin activity (du Cailar et al 2000). 
  
 
Figure 1.4: Schematic Diagram of the four Geometric Patterns (Adapted from 













 1.7     Pathogenesis of Left Ventricular Hypertrophy 
Two major triggers for LVH are biomechanical stress and neuro-hormonal factors. LVH 
is mainly due to pressure or volume overload on the heart. Common causes of pressure 
overload are systemic hypertension, aortic stenosis, coarctation of the aorta and 
hypertrophic cardiomyopathy. It is thought that a mechanical signal initiates a cascade of 
biological events which lead to co-ordinated cardiac growth. There is then an increased 
myosin heavy chain synthesis (by about 35%) within hours of pressure overload. This 
increase is initially predicted by an increase in translational efficiency (Imamura et al 
1994). 
This hypertrophy leads to complex changes in gene reprogramming. These changes 
include re-expression of immature foetal cardiac genes including: (i) genes that modify 
motor unit composition and regulation; (ii) genes that encode hormonal pathways, e.g 
atrial natriuretic factors, and (iii) genes that modify energy metabolism (Swinghedauw et 
al 1999). Neurohormonal factors that have been implicated in left ventricular hypertrophy 




It has been postulated that angiotensin II, via the AT1 receptor, plays a key role in the 
induction of hypertrophy because it can directly induce the molecular events of early 
cardiac growth. Some workers (Sadoshima et al 1993; Harrap et al 1996) in a study of 
84 young healthy subjects, aged 16–24 years, found a direct role for angiotensin II in the 
development of LVH. Cardiac rennin-angiotensin system has been proposed as an 
important determinant of hypertrophic response (Dzau et al 1993). The importance of 
angiotensin II in the development of LVH in hypertensive subjects is also suggested 
indirectly by the observation that an ACE inhibitor causes regression of left ventricular 
hypertrophy, more than other antihypertensive drugs (Schmiedert et al 1996). 
Endothelin 
Some animal studies suggest that endothelin plays a role in the development of left 













Calcineurin is a calcium calmodulin–dependent phosphatase. It serves as a master 
switch for clinical hypertrophy. In animal studies, that transgenic mice that over-express 
components of the calcineurin signalling pathway, develop a hypertrophic phenotype 
that can be expressed by pharmacological inhibitors of calcineurin (Molkentin et al 
1998). 
Metalloproteinase (MMPs) 
Matrix metalloproteinase is a family of zinc dependant interstitial enzymes. Their tissue 
inhibitors (TINIPs) control the breakdown of collagen (Woessner et al 1991). The role of 
MMPs in concentric hypertrophy is not fully understood, but preliminary observations 
show that they are activated in experimental pressure overload hypertrophy. Studies 
have also shown that imbalance between MMPs and TINIPs could lead to LVH and 
diastolic dysfunction (Saglam et al 2006; Ahmed et al 2006). 
 
Heterometrimeric G Proteins 
Many hormones and neurotransmitters implicated in the initiation and exacerbation of 
myocardial hypertrophy including angiotensin II and endothelin, bind to cell membrane 
receptors which couple to a subset of intracellular heterometrimeric G proteins – the G 
(q) class (Akhter et al 1998).  
 
1.8  Progression of Hypertension to Hypertensive Heart Failure  
This aspect of Cardiovascular Medicine is still highly debated. One theory puts it that the 
pathogenesis of hypertensive heart failure involves a stepwise progression from 
hypertension to left ve tricular hypertrophy, to heart failure with preserved systolic 
function and eventually to ventricular dilatation and cardiac failure (Izzo JL et al 2004). 
An important parallel route to heart failure involves loss of cardiac myofibrils from 
ischaemic heart disease, which leads directly to segmental wall motion abnormalities 
and systolic dysfunction (Izzo JL et al 2004). Figure1.5 shows the possible pathways for 
the progression of hypertensive LVH to hypertensive heart failure and these include: 
progression of hypertension to concentric LVH, progression of hypertension directly to 
hypertensive heart with dilated left ventricle and reduced left ventricular systolic function 
with or without myocardial infarction, progression of hypertension through concentric 
hypertrophy to heart failure without or without transient myocardial infarction with 












concentric hypertrophy to heart failure with preserved ejection fraction. In hypertensive 
subjects in sub-Saharan Africa with the relative low prevalence of coronary artery 
disease (Damasceno et al 2012), progression of hypertension either directly to heart 
failure or through concentric LVH without transient myocardial infarction are favoured.  
Mechanisms that lead to ventricular dilatation in individuals with decompensating LVH 
are not completely understood at present (Frohlich ED et al 2003). In patients with 
systolic dysfunction, activation of the sympathetic nervous and renin-angiotensin-
aldosterone systems causes vasoconstriction, salt and water retention and progressive 
ventricular dilatation and remodelling has been implicated. All the above mentioned 
processes are maladaptations that create a vicious cycle that worsens cardiac 
performance (Williams RS et al 1999). As cardiac function declines, there is no further 
increase in left ventricular mass due to increased apoptosis (Sun Y et al 1998).  
In the myocardium the altered gene expression pattern that accompanies the transition 
from LVH to heart failure includes an overall decrease in contractile proteins 
(Rerkpattanapipat P et al 2002).  At the same time, interstitial protein synthesis 
continues leading to myocardial stiffness, impaired diastolic relaxation and reduced 
exercise tolerance (Rerkpattanapipat P et al). Ultimately, there is reduced myofibrillar 
efficiency, ventricular dilatation and heart failure (Weber KT et al 2001). In addition, 
concomitant large and small blood vessel changes exacerbate the progression from left 
ventricular hypertrophy to heart failure. The aorta becomes stiffer with impairment of 
ventricular-vascular coupling and increased cardiac afterload (Chae CU et al 1999). 
Coronary flow reserve is also diminished by left ventricular hypertrophy and is eroded 














Figure 1.5: The Possible Pathways in the Progression from Hypertension to 





1.9  CLINICAL SIGNIFICANCE OF LVH  
Left ventricular wall hypertrophy has been found to be an independent cardiovascular 
risk factor. It is as potent as systolic blood pressure or age in predicting future 
cerebrovascular accident, myocardial infarction, sudden death or heart failure (Kannel et 
al 2003). Bouzas-Mosquera (Bouzas-Mosquera et al 2012) showed in 40138 subjects 
with echocardiographic determined left ventricular wall hypertrophy, with a mean age of 
61.2 years, who were followed up for an average period of 5.7 years, that 9181 subjects 
died, 901 had nonfatal myocardial infarction and 2139 had nonfatal stroke. Cumulative 
10-year mortality was 26.8%, 31.9%, 37.4% and 46.4% in patients with normal, mildly, 
moderately and severely increased left ventricular mass, respectively (p<001). Ten-year 
rates of nonfatal myocardial infarction and stroke ranged from 3.2% and 6.7% in patients 
with normal left ventricular mass to 5.3% and 12.7% in those with severe increase in left 
ventricular mass, respectively. After multivariate adjustment, left ventricular mass 
remained an independent predictor of all-cause mortality (hazard ratio per 100g increase 
of 1.21, 95% confidence interval of 1.14–1–27 and p-value<0.001 in women, and hazard 












infarction hazard ratio was 1.60,  with 95% confidence interval of 1.31–1.94 and p-value 
<0.001 in women, and for men hazard ratio was 1.15,  with 95% confidence interval of  
1.02–1.29 and p-value = 0.019. Lastly, for stroke hazard ratio was 1.26 with 95% 
confidence interval of 1.13–1.40 and p-value <0.001 in women, while in men hazard 
ratio was 1.19 with 95% CI of 1.09–1.30 and p-value<0.001. They concluded that left 
ventricular hypertrophy has a graded and independent association with all-cause 
mortality, myocardial infarction and stroke. 
The presence of electrocardiographic–determined LVH (ECG-LVH) has been found to 
roughly double the risk of subsequent cardiovascular events or death.  This is 
irrespective of race, sex or history of prior coronary artery disease (Vakili et al 2001). 
Increased ECG voltage in hypertensives also correlates with increased incidence of 
heart failure episodes (Aronow et al 1998). In echocardiography–based studies, the risk 
factor–adjusted relative risk of cardiovascular disease was found to be about 50% 
greater for each increase of 50g/m2 in left ventricular mass in men or women (Kannel 
WB et al). In general, LVH increases cardiovascular disease mortality by about 75% in 
men and roughly doubles it in women, with a similar impact on all–cause mortality (Levy 
et al 1998; Levy et al 1989; Levy 1990).  
Studies from the Framingham Heart Study have without doubt shown the prognostic 
value of echocardiographically detected LVH. Echocardiographically detected LVH has 
been shown to identify a population at high risk for cardiovascular disease (Levy  et al 
1992). Subjects with left ventricular hypertrophy were found to be older, had higher 
blood pressure, were more obese and more likely to have pre-existing coronary artery 
disease and depressed left ventricular systolic function (Levy et al 1990).  
Echocardiographic LVH also predicts increased risk of cardiovascular morbidity and 
mortality, even after adjustment for other major risk factors such as age, systolic and 
diastolic blood pressure, pulse pressure, treatment for hypertension, smoking, diabetes, 
obesity, dyslpidaemia, and electrocardiographic evidence of LVH (Haider et al 1998). In 
apparently healthy subjects followed for a period of  4 years, in whom LVH was defined 
as left ventricular mass, adjusted for height of 143 g/m in men and 102 g/m in women, 
the relative risk of developing cardiovascular disease was 1.49 in men and 1.57 in 
women for each increment of 50 g/m in LV mass. This increment of LV mass was also 
associated with a relative risk of cardiovascular death of 1.73 in men and 2.12 in 
women, and a relative risk of all-cause death of 1.49 in men and 2.01 in women. LVH is 












pronounced in men than in women (Krumholtz HM et al 1998). LVH in women is now 
considered to be a strong cardiovascular risk factor independent of blood pressure (Liao 
et al 1995, Wassertheil-Smoller et al 2004) and some studies have revealed an 
increased incidence of atrial fibrillation and sudden death in women with LVH. Patients 
with hypertensive LVH are at an increased risk of progressing to left ventricular systolic 
heart failure. Figure 1.6 shows the summary of the effect of LVH on cardiovascular 
endpoints and Figure 1.7 further illustrates the fact that amongst the four geometric 
patterns concentric hypertrophy has the least survival.  
      
 
Figure 1.6: Effect of LVH on Cardiovascular Endpoints  
Composite endpoint of cardiovascular death, fatal or non-fatal myocardial infarction, and 
fatal or non-fatal stroke stratified by the time-varying presence of left ventricular 
hypertrophy (LVH) on echocardiography in the Losartan Intervention for Endpoint 














Figure 1.7: Effect of LV Geometry on Survival  
Actuarial cumulative hazard plot for survival time based on cardiac structure. A (left), 
Normal structure, concentric remodelling (CR), and frank left ventricular hypertrophy 
(LVH). B (right), Normal structure, concentric remodelling (CR), eccentric hypertrophy 
(adapted from Devereux et al 2004). 
 
1.10  Assessing Left Ventricular Hypertrophy 
The most common ways of assessing left ventricular wall hypertrophy is by 
electrocardiography and transthoracic echocardiography. Electrocardiography is cheap 
and more widely available, compared to transthoracic echocardiography. However, 
compared with echocardiography criteria for LVH, electrocardiography has extremely 
low sensitivity and exhibits limited accuracy (Levy et al 1990).  
In a review of the role of electrocardiograhy in detecting LVH with strain pattern, the 
prevalence of electrocardiographic strain pattern ranged from 2% to 36% with the 
highest prevalence occurring in the era before good antihypertensive therapy. The 
sensitivity as a measure of LVH ranged from 2% to 36% (Ogah et al 2006). 
Electrocardiography has also been found to have low sensitivity for detecting magnetic 
resonance imaging defined LVH (Jain A et al 2010).  
An example of the limitation of electrocardiography is seen in the Heart of Soweto Study 
in which 387 electrocardiographic recordings subjects, found to be heart disease free on 
echocardiography, showed that  51% had an ECG “abnormality” or normal variant and 













Index voltage exceeding 38mm, indicative LVH, were found to be more prominent in 
males than females(23.6% vs.6.4%; OR=4.5; 95% CI 2.3-8.5) (Sliwa et al 2012).  
In another study of 334 Africans, the performance of classic electrocardiographic criteria 
for the detection of LVH was largely disparate and appeared to be lower than in 
Caucasians (Jaggy et al 2000).  
Pathological left ventricular wall hypertrophy may be associated with non-existence of 
symptoms for many years before the development of complications such as congestive 
heart failure or unexpected sudden death. Therefore, in contemporary clinical practice 
and population studies, the diagnosis of LVH depends predominantly on 
echocardiographic measurements or novel non-invasive imaging techniques. Two-
dimensional targeted M-mode echocardiographic measurements of LV dimensions and 
the calculation of LV mass are now standardized (Vuille et al 1994). The detection of 
pathological LVH requires adjustments for sex, height, and body mass. Even though 
multiple studies have offered echocardiographic criteria for LVH, the analyses of the 
large original cohort and offspring subjects of 56148 of the Framingham Heart Study 
have provided criteria that are based on a healthy population distribution of LV mass 
(Levy  et al 1987). Using these mass/height criteria, the prevalence of LVH in the entire 
Framingham Study population was 16% in women and 19% in men. Echocardiographic 
LVH is also more prevalent than LVH detected by electrocardiography, with overall rates 
of 17.4% versus 2.4%, respectively (Levy  
et al 1987). Normal ranges of LV and right ventricular mass have been described in 
healthy male and female subjects using cine-MRI, as well as ultrafast CT. In a recent 
study of 75 healthy subjects, the upper limit (95% confidence limit) of LV mass 
normalized to body surface area was 113 g/m2 in men and 95 g/m2 in women (Lorenz 
et al 1999). The review by Lorenz et al (Lorenz et al 1999) summarizes normative sex-
based values of LV mass reported by additional contemporary MRI and CT studies. In 
comparison with the Framingham Heart Study, which used echocardiographically 
detected LVH, current novel imaging studies are limited by the much smaller size of the 
study populations and less robust longitudinal outcome data.  
Although, the awareness and availability of echocardiography in sub-Saharan Africa is 
increasing, it is still not widely accessible because of high cost (Reichek et al 1981; 
Adamu et al 2001). Transthoracic echocardiography results may also not be adequate in 
all patients, especially in those with obesity and pulmonary disease (Levy et al 1990; 












especially in sub-Saharan Africa, there is the need for cardiovascular scientists to turn to 
biochemical markers such as NT-Pro BNP, BNP and other novel biomarkers which can 
be used to evaluate various spectrum of hypertension, hypertensive heart disease and 
hypertensive heart failure (Buckley et al 1998). 
 
1.11  Hypertensive Heart Failure 
Heart failure is a very dominant health issue in developed societies and the most 
common cause of hospital admission for patients over the age of 65 years. It is also the 
single most important consumer of healthcare dollars (Vasilios et al 2001). In some 
European countries and the United States, as much as 1% of the health budget is spent 
on the management of heart failure. In the United States in-patient treatment of heart 
failure accounts for about thirteen billion US dollars per year and the amount spent on 
outpatient management is at least four times higher. 
 
With improvements in the control of communicable diseases, malnutrition and rapid 
urbanisation, cardiovascular diseases such as hypertension and cerebrovascular 
accident are increasingly recognised as significant causes of morbidity and mortality in 
most African countries (Muna et al 1993). Nowadays, cardiovascular diseases account 
for 7 – 10% of all medical admissions to hospital, with heart failure contributing 3 – 7% 
(Onwuchekwa  et al 2009).  
Hypertension is the most common cause of heart failure and most patients who develop 
heart failure have a history of hypertension (Vasilios et al 2004). In the Global Burden of 
Disease 2010 Project (Murray CJL et al 2010), hypertensive heart disease which 
comprises hypertension, hypertension with LVH and hypertensive heart failure, was 
ranked one of the most common causes of disability adjusted life years. In a study by 
Perera before the availability of effective anti-hypertensive drug therapy, of the 500 
patients with uncontrolled hypertension followed for over 20 years, 50% died of heart 
failure (Perera et al 1995).  In the Framingham Heart Study, hypertension accounted for 
39% of heart failure in men and 59% in women (Levy et al 1989; Levy et al 1990; Vasan 
et al 1990). 
In a recent survey of the causes, treatment and outcome of acute heart failure in 1006 
Africans from nine sub-Saharan Africa countries, heart failure was most commonly due 












African population, hypertension is the leading cause of heart failure in Nigerians 
accounting for about 60% (Ojji et al 2009; Onwuchekwa et al 2009). Hypertension is also 
the leading cause of heart failure in Cameroon, accounting for about 54% of all heart 
failure cases (Kinque et al 2005). In 1960 cases of heart failure studied in  the Heart of 
Soweto study, hypertensive heart failure accounted for the highest form of heart failure 
in 281 (33%) of the study cohort (Stewart S et al 2008). 
In a recent publication of the Abuja Heart Study (Ojji et al 2013), in a cohort of 1,515 
subjects attending a cardiac clinic in a tertiary set up, hypertensive heart failure was the 
commonest form of heart failure in 60% of cases and accounted for 33% of the total 
cohort.  
 
1.12. BNP and NT-Pro BNP in Hypertensive Heart Disease 
 BNP and NT-pro BNP  
BNP consists of 32 amino-acids with a central ring of 17 amino-acids created by a 
disulphide bond between cystine bases (Cowie et al 2002). Figure 2: Structure of Pro 
BNP and NT-pro BNP. BNP is secreted by myocardial cells located on both atria and 
ventricles, mainly by left ventricular myocardial cells. BNP’s gene is located on the short 
arm of chromosome 1, close to the ANP loci. Its mRNA is translated to a chain of 108 
amino acids called pro BNP that co-exist with ANP in some secretory vesicles of the 
atrial and ventricular myocardial cells. Pro BNP is transformed to BNP and to NT-pro 
BNP, an endocrinologically inactive molecule (Bolger et al 2002; Kroger 2002). 
           
BNP and NT- pro BNP in Assessing Hypertensive Heart Disease 
Left ventricular hypertrophy has been reported as one of the conditions in which plasma 
BNP and NT-pro BNP significantly exceed the normal range (Takeda et al 1995). 
Plasma BNP level has been found to be a useful marker of left ventricular hypertrophy in 
hypertension and has been found to rise progressively with increasing severity of 
hypertension, particularly when ventricular hypertrophy is present. Similarly, it has been 
shown by some other workers (Santiago et al 2009) that plasma BNP and NT-pro BNP 
levels are useful to discriminate between patients with regard to cardiac remodelling, 
and they suggested that they should be considered as a screening tool in order to select 












more recent study, NT-pro BNP has been found as an independent predictor of survival 













Figure 1.8: Structure of BNP and NT-PRO BNP 
 
 Plasma BNP and NT- pro BNP in Heart Failure    
The usefulness of BNP in heart failure can be divided into three, which include making of 
diagnosis, prognostication of disease conditions and assessment of therapy. 
 
Making Diagnosis 
Its usefulness in diagnosis covers conditions such as left ventricular diastolic 
dysfunction, left ventricular systolic dysfunction after acute myocardial infarction and 
right ventricular heart failure. It has been proposed that patients with BNP 
concentrations of less than 20pmal/L have less chances of suffering from heart failure, 
while patients with higher concentrations should have further cardiovascular 
investigations (Talwar et al 2000, Hunt et al 1997).  Recent studies in patients with 
normal systolic function verified by echocardiography have shown that BNP levels 
correlate well with Doppler measurements showing diastolic dysfunction of the left 
ventricle (Moser et al 2002). Theoretically, NT- pro BNP is said to be better in identifying 
patients with heart failure. Its increase is also said to be greater than that of BNP and its 















Prognostication of Disease Conditions Using BNP and NT-Pro BNP 
Published studies indicate that that BNP or NT-pro BNP plasma concentration provides 
important information on the prognosis of heart failure and support its use as an 
adjuvant to clinical assessment especially in centres where risk stratification is of great 
importance, for example in transplantation units (Hasegawa et al 1993). In eight 
randomized controlled trials with a total of 1726 patients with a mean duration of 
16 months, B-type natiuretic peptide-guided therapy was found to reduce all-
cause mortality in patients with chronic heart failure compared with usual clinical 
care especially in patients younger than 75 years (Parapakkham et al 2010). 
 
Assessment of Therapy 
It has also been found out that assessing BNP levels and adjusting the dosage of 
therapy according to its level can lead to achieving the best possible treatment of heart 
failure (Cowie et al 2002). It has been shown by these workers that BNP concentration 
of less than 100pg/ml correlates with functional improvements in patients with heart 
failure and also linked to decreased clinical endpoints, such as cardiovascular death. 
They further suggested that using BNP concentrations to monitor patients with heart 
failure and managing their medical therapy accordingly might improve overall morbidity 
and mortality.  
  
Choosing NT-pro BNP ahead of BNP 
Measuring NT-pro BNP has significant advantages over routine BNP, even though the 
levels of the two will be the same under ideal circumstances. NT-pro BNP is more stable 
than BNP with a half-life of 60-120 minutes, as against a half-life of 18-22 minutes for 
BNP. Once blood is collected BNP levels are not stable in vitro for long periods, 
dropping significantly over the first 24 hours, while there is very little variation in the level 
of NT-pro BNP for at least 72 hours or even longer. Therefore, NT-pro BNP can be 
assayed from stored or delayed specimens with confidence that the levels have not 












than assaying BNP and this is because of higher plasma concentration. NT-pro BNP has 
also been found to be better in identifying patients with heart failure. Its increase in heart 
failure has also been found to greater than that of BNP and its plasma concentration is 
more stable (Kohno et al 1992; Nishigaki et al 1996) 
 
. 
1.13 Novel Biomarkers of Hypertension, Hypertensive Heart Disease and 
Hypertensive Heart Failure 
In the last few years, the identification of biomarkers of potential usefulness for the 
clinical handling of hypertension evolving to hypertensive heart disease and 
hypertensive heart failure has been a prolific field (Arantxa et al 2009). The rapid 
acceleration of the investigation of novel circulating biochemical markers of myocardial 
remodelling in hypertensive heart disease has also caused the clinical and research 
communities to be faced with candidate molecules of which very few are likely to survive 
the test of time as useful clinical tools (Vasan et al 2006; Morrow et al 2007). 
A number of the biochemical markers that have been studied include Cardiotrophin-1, 
Annexin A5, Carboxy-terminal pro-peptide of procollagen type 1 and Matrix 
metalloproteinase-1. Cardiotrophin-1 appears to be the most promising of these markers 
as regards the criteria for the ideal biochemical marker (Arantxa et al 2009).  
Cardiotrohin-1 is a cytokine member of the interleukin-6 super family which is produced 
by cardiomyocyte and cardiac fibroblasts in situations of biochemical stress and under 
exposure to humoral factors such as angiotensin II (Kuwahara et al 1991; Sano et al 
2000). Once it is secreted it interacts with its receptor, which is an heterodimer formed 
by glycoprotein 130 and the leukaemia inhibitory factor receptor activating different 
signalling pathways thereby leading to cardiomyocyte growth dysfunction (Pennica et al 
1996). 
Plasma cardiotrophin-1 concentration has been found to be increased in hypertensive 
patients as a whole group, compared to normotensive subjects (Lopez et al 2006; 
Pemberton et al 2005). It has also been reported that plasma cardiotrophin-1 is higher in 
patients with LVH than in patients without LVH (Lopez et al 2005), and in patients with 
heart failure than in patients with LVH (Asal et al 2000). In addition, it has been found 
out that 31% of hypertensive patients without LVH already exhibited concentrations of 












normotensive control population which suggests that cardiotrophin-1 increases early in 
the evolution of arterial hypertension (Gonzalez et al 2007). 
An association exists between anti-hypertensive-induced decrease of plasma 
cardiotrophin-1 and reduction of left ventricular mass index in patients with left 
ventricular hypertrophy (Gonzalez et al 2005).  Abnormally high plasma cardiotrophin-1 
concentration is associated with reduced fractional shortening and altered relaxation in 
patients with inappropriate left ventricular mass (Lopez et al 2007). 
Lastly, cardiotrophin-1 presents an acceptable sensitivity of 70% and specificity of 75% 
to detect LVH, as assessed by echocardiography in hypertensive patients (Lopez et al 
2007). 
 Soluble ST2 as a Novel Biomarker 
The most recent novel biomarker is soluble ST2. The ST2 receptor is a member of the 
Toll-like/interleukin-1 (IL-1) receptor family. A large amount of research work in animal 
models have shown that cytokine IL-33 interacts with ST2 receptors in cardiac 
myocytes, thereby comprising a cardio protective stress-responsive signaling system 
(Kakkar et al.2008; Sanada et al 2007). ST2 exists in two forms - transmembrane and 
soluble forms. Soluble ST2 is a candidate of biomarker in cardiovascular disease. It was 
shown that mice treated with exogenous IL-33 demonstrate reduced hypertrophy and 
transgenic deletion of ST2 abolishes this salutary effect, thereby resulting in severe 
myocardial hypertrophy and fibrosis (Sanada et al 2007). Figure 3 shows the structure of 
ST2. 
 
In response to inflammation and cardiac stress, IL-33/ST-2 signaling becomes activated 
and the soluble form of ST2 is released into the circulation (figure 1.6). The soluble form 
of ST2 acts as a decoy receptor, sequestering and inhibiting IL-33 and this potentially 
explains why we, and others, have observed that higher circulating levels reflect 
increased cardiac risk (Kakkar et al 2008). Genomic technology has been used to 
identify ST2 as a gene markedly induced in mechanically overloaded cardiac myocytes 
(Weinberg et al 2002; Weinberg et al 2003). 
The above point further suggests that ST2 is induced in conditions of myocardial 
overload, such as myocardial infarction, when the remaining viable myocardium must 
bear more stress. Soluble ST2 have been found to be increased in the serum of patients 












patients with heart failure and a change in ST2, over time, is also associated with 
prognosis. 
Although the lung has been shown to have the highest expression of soluble ST2 levels 
(Mildner et al 2010), potential cellular sources of soluble ST2 in the cardiovascular 
system include endothelial cells (Bartunek et al 2008; Aoki et al 2010) and cardiac 
myocytes (Mildner et al 2010). 
The first study to demonstrate that serum soluble ST2 level was elevated early after 
acute myocardial infarction was carried out in sixty nine human samples and showed 
that soluble ST2 levels correlated with creatinine kinase and correlated inversely with left 
ventricular ejection fraction (Weinberg et al 2002). Two larger studies have since 
demonstrated the prognostic value of measuring serum soluble ST2 in acute myocardial 
infarction. Shimpo et al (Shimpo et al 2004) measured serum soluble ST2 in eight 
hundred and ten (810) patients with acute myocardial infarction (AMI) in the 
Thrombolysis In Myocardial Infarction (TIMI)-14 and Enoxaparin and TNK-tPA with or 
without Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor as Reperfusion Strategy in 
STEMI(ENTIRE)-TIMI-23 clinical trials. They demonstrated in these two studies that 
baseline levels of soluble ST2 were higher in patients who died or developed congestive 
heart failure.  
Soluble ST 2 levels were also measured in 1239 patients from the Clopidogrel as 
Adjunctive Reperfusion Therapy=Thrombolysis in Myocardial Infarction 28 (CLARITY-
TIMI 28) trial (Sabine et al 2008). The authors found that high levels of soluble ST2 at 
baseline were a significant predictor of cardiovascular mortality and heart failure and 
combined measurement of ST2 and NT-pro BNP significantly improved prediction of 
cardiovascular death. Measurement of soluble ST2 early after acute myocardial 
infarction in one hundred patients undergoing cardiac Magnetic Resonance Imaging also 
assisted in the prediction of adverse left ventricular functional recovery and remodelling 
(Weir et al 2010). In an outpatient study, soluble ST2 levels also reflected right-side 
heart size and function, and these were an independent predictor of one-year mortality 
in outpatients referred for echocardiography (Daniels et al 2010). 
Several other studies have obtained similar findings that soluble ST2 levels correlate 
with severity of heart failure, left ventricular ejection fraction, creatinine clearance, B-type 
natriuretic peptide, C-reactive protein and are a predictor of mortality (Boisot et al 2008; 
Mueller et al 2008; Pascual-Figal et al 2009; Bayes-Genis et al 2010). Concentrations of 












and without acute destabilized heat failure (Januzzi et al 2007; Martinez-Rumayor et al  
2008; Mueller et al 2008; Januzzi et al  2008; Shah et al 2009; Dieplinger et al.,2010).  
In addition, cardiac surgery patients undergoing coronary artery bypass grafting with 
cardiopulmonary bypass demonstrate a significant rise in soluble ST2 levels twenty four 
hours after surgery (Szerafin et al 2005; Szerafin et al 2009). Putting all these things 
together, these studies indicate soluble ST2 has the potential to be a predictive 







Figure 1.9: The structure of ST2 and Activation of ST2 Receptor (adapted from 
Miller Am et al 2011).IL-33 that is secreted by necrotic cells can  activate the 
heterodimer ST2/Il-1RAcp receptor complex leading to the recruitment of MyD88  and 
IRAK 1 and 4, and activation of two other pathways as shown above. 
 
1.14  Problem Statement and Rationale 
In black Africans, primary hypertension is the most common cardiovascular risk factor 












(Seedat et al 2000). In a recent systematic review of 25 studies from 10 sub-Saharan 
African countries, prevalence of hypertension ranged from 13 – 48% with rural to urban 
gradient (Addo J et al 2007). 
Common complications of hypertension in black Africans, apart from cerebrovascular 
accident and chronic kidney disease, are LVH and heart failure. Since the burden of 
hypertensive heart disease is enormous in black Africa, there is the need to look for 
easier and faster bedside means to differentiate between the various spectrums of 
hypertensive heart disease, as this affects the prognosis, management and treatment 
modalities in hypertension. 
 
Hypertensive Heart Disease: A big burden-the need for point-of-care screening 
There is a need to differentiate the various spectrum of hypertensive heart disease early 
as this will determine the various therapeutic approaches, such as the initiation of agents 
such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers and 
beta-1-selective agents. A biomarker which can be used as point-of-care by the bedside 
will be necessary. Although more conventional electrocardiography and 
echocardiography are the diagnostic tools in this regard, electrocardiographic criteria are 
insensitive, while echocardiography is not so easily accessible, uneconomical and may 
not be adequate in all patients, especially in those with obesity or pulmonary disease. In 
most parts of sub-Saharan Africa people either have to travel long distances or wait for a 
very long period of more than four months to have transthoracic echocardiography 
performed. 
 
Early detection of concentric hypertrophy amongst left ventricular hypertrophy 
LVH is classified according to geometric pattern into four types, which are concentric 
hypertrophy, eccentric hypertrophy, concentric remodelling and normal geometry 
(Ganau et al 1992). Patients with concentric LVH have a higher prevalence of 
associated cardiovascular complications or death than those with other geometric 
patterns. This is illustrated in figure 2.0 which shows the mortality in four geometric 
patterns, in 9771 elderly patients, and is further illustrated in figure 2.1, which also 
shows mortality in four left ventricular geometric patterns in 11792 obese patients with 
preserved ejection fraction. These figures highlight that concentric hypertrophy have 












concentric hypertrophy also have the most advanced extra-cardiac target-organ 
damage, compared with other groups (Koren et al 1991) and, therefore, there is the 
need for early diagnosis and instituting of therapy with medications, including the rennin-
angiotensin-aldosterone blockers for patients with LVH, especially concentric 
hypertrophy. Since echocardiography is not easily accessible, especially in resource 
poor settings, and there may be problems of interpretation in those with obesity or 
pulmonary disease, there is therefore the need for cardiovascular scientists to look for 
easier and more accurate methods, especially at the bedside, of assessing the cardiac 
structural changes in hypertension. One biomarker that has been found to be a marker 
of left ventricular remodelling in hypertension in Caucasians is BNP (brain natriuretic 
peptide) and NT- pro BNP.  Another biomarker that has been found by cardiovascular 
scientists as a biomarker for cardiovascular diseases is soluble ST2, which is a member 
of the interleukin-1 receptor host defence and inflammation family. 
 
 
Figure 2.0: Mortality in 4 left ventricular geometric patterns in 9771 elderly 
patients aged more than 70 years with normal ejection fractions (adapted from 














Figure 2.1: Mortality in 4 left ventricular geometric patterns in 11 792 obese 
patients with preserved ejection fraction (Milani et al 2006). CR=Concentric 
remodelling, EH=Eccentric Hypertrophy, CH=Concentric Hypertrophy. 
 
NT-pro BNP as a valid Biomarker in Hypertensive Heart Disease in sub-Saharan Africa  
Plasma BNP and NT-pro BNP levels have been found to be a marker of left ventricular 
hypertrophy in hypertension and has also been found to rise progressively with 
increasing severity of hypertension, particularly when ventricular hypertrophy is present. 
Similarly, it has been shown by some other workers (Buckley 1993) that plasma BNP 
and NT-pro BNP levels differentiate patients with regard to cardiac remodelling and they 
have suggested that they should be considered as a screening tool in order to select 
hypertensive patients eligible for transthoracic echocardiography. In addition, NT-pro 
BNP has been shown to be a biomarker that differentiates hypertensive subjects with left 
ventricular wall hypertrophy from those with heart failure (Santiago et al 2009, Talwar et 
al 2000). Most of the current knowledge and published data on plasma NT- pro BNP as 
a marker in hypertensive left ventricular hypertrophy and hypertensive heart failure are 
based on studies in Europe and the United States of America, with a dearth of data in 
Africans, where the burden of hypertension and hypertensive disease is very high 
(Stewart et al 2011; Ojji et al 2013). For example, the THESUS study, which studied 












Nigeria, showed that hypertension was the most common cause of heart failure, 
accounting for heart failure in 45.4% of cases (Damasceno et al 2012). In addition, most 
previous studies on this subject never considered left ventricular diastolic function or 
right ventricular function, both which have been found to be prognostic markers in 
hypertensive heart disease (Myslinski et al 1998; Giuseppe et al 2002). We therefore 
proposed to examine the effect of NT- pro BNP on left and right ventricular remodelling 
in an African Hypertensive cohort. 
 
ST2 as a Possible Biomarker in Hypertensive Heart Disease  
Soluble ST2 is a member of the interleukin-1 receptor host defence and inflammation 
family (O’Neil et al 2000, Shimpo et al 2004). Soluble ST2 is induced in conditions of 
myocardial overload, such as acute myocardial infarction, when the remaining viable 
myocardium must bear more mechanical stress (Shimpo et al 2004,Townsend MJ et al 
2000) and has also been recently reported to be increased in hypertension (Coglianese 
et al 2012). In spite of the use of serum soluble ST2 as a marker in the field of 
cardiovascular medicine, there is a global dearth of data on the role of soluble ST2 in 
hypertensive heart disease. We therefore proposed to study the role of soluble ST2 in 
differentiating the various spectrum of hypertensive heart disease, with the ultimate goal 
of developing a point of care for early and easy differentiation of the various spectrum of 
























2.0  Aims, Hypothesis and Objectives 
2.1 Background 
Although hypertension affects every ethnic group, the consequences are said to be 
more devastating among blacks. One of the main manifestations of hypertension’s end-
organ effects especially in blacks is hypertensive heart disease which includes LVH, 
increasing vascular and ventricular stiffness and diastolic dysfunction which ultimately 
lead to heart failure (HF) if not adequately treated.  
In spite of the high burden of hypertension, hypertensive left ventricular wall hypertrophy 
and hypertensive heart failure and the limitations of electrocardiography and 
transthoracic echocardiography as diagnostic tools in these conditions, there is a paucity 
of data in the sub-Saharan African population on the use of both conventional and novel 
biomarkers as screening and diagnostic tools in hypertension, hypertensive left 
ventricular hypertrophy and hypertensive heart failure. 
The aim of this study was therefore to explore the role of conventional biomarker NT-pro 
BNP and the novel biomarker ST2 in differentiating the various spectrum of 
hypertension-hypertensive heart disease with the ultimate goal of developing point of 
care tests to complement the more conventional electrocardiography and 
echocardiography. 
 




We hypothesise that the biomarker NT-pro BNP can differentiate a hypertensive cohort 
with/without left ventricular hypertrophy from hypertensive patients with heart failure, 
but will not be sensitive enough to differentiate hypertensive subjects with left 
ventricular hypertrophy from patients without left ventricular hypertrophy. We also 
hypothesise that the novel biomarker ST2 is a more sensitive biomarker than NT-pro 












2.3 What are the aims of this study? 
To fulfill the aims of the present study the following objectives as shown in figure 2.1 
were pursued:  











I. To describe the demographic and clinical characteristics of  the 
subjects  
 
II. To examine the effects of the spectrum of hypertensive heart 
disease on plasma concentrations of NT-pro BNP and soluble 
ST2 
 
III. To study the relationship between ventricular remodeling and NT-
pro BNP and soluble ST2 
 
IV. To describe the relationship between different LV geometric 
patterns and NT-pro BNP and soluble ST2 
 
V. To determine the prevalence of right ventricular systolic 
dysfunction in the hypertensive heart failure subjects     
 













3.0  METHODS 
3.1  Study Group 
This is a prospective cohort study. The study was approved by the University of Abuja 
Teaching Hospital Ethical Clearance Committee (approval number: 
UATH/HREC/PR/233) and is in compliance with the Helsinki declaration. The minimum 
age for participation in the study was 18 years, but there was no upper age limit. 
Recruitment for the present study was initiated in December 2011 and data were 
obtained until August 2012. Of the two-hundred and twenty (220) subjects with 
hypertension, with or without heart failure, enrolled for the study, ten representing 4.5% 
of the total enrolment were excluded because they were either diabetic (1.8%), had 
regional wall motion abnormality on trans thoracic  echocardiography (0.9%), had serum 
creatinine greater than 170µmol/l (1.4%) or had acute myocardial infarction (0.4%). 
Therefore, two-hundred and ten (210) were studied. One hundred and thirty three (133) 
were subjects with new referral for hypertension to the Cardiology Unit, Department of 
Medicine, of the University of Abuja Teaching Hospital, and another seventy seven (77) 
were subjects with hypertensive heart failure presenting to the same unit. A study 
population of 210 subjects gave a study power of 100% and a chi-square value of 
89.8 using a two-degree of freedom chi-share test. 
The University of Abuja Teaching Hospital, comprising three-hundred and sixty (360) 
beds, is the largest hospital serving the Federal Capital Territory (FCT) of Nigeria, which 
has a population of over two million. The Cardiology Unit has the services of three 
cardiologists, five interns in training, three house physicians and five trained nurses. The 
subjects were typically referred by both general and family physicians in primary and 
secondary healthcare settings, including private facilities. Subjects were, on average, 
public servants, traders, artisans, politicians, farmers, retired public servants and health 
workers.  
Hypertension was defined according the JNC VII guidelines (JNC et al 2004),while heart 
failure was diagnosed according to the European Society of Cardiology (ESC Task 
Force 2005) Guidelines, as shown in table 3.1 and functional status of the heart failure 
subjects was according to the guidelines of the New York Heart Association Functional 













Each subject had fasting blood sugar, fasting lipid profile, electrolyte, urea and creatinine 
and full blood count assessed. Blood chemical analysis was performed at a central 
certified laboratory. Fasting blood sugar and fasting lipid profile were analysed by auto 
analyzer (Erber Spectrophotometer, Boehringer GmBH, Mannheim, Germany). Each 
subject also had blood collected, processed and plasma stored at -80 degrees Celsius 
until assayed for NT-pro BNP. They also had a transthoracic echocardiography 
performed the same day that the sample was collected for NT-pro BNP. 
 
3.2 Questionnaire 
All the subjects completed a standard questionnaire. Due to the multiplicity of languages 
in Nigeria, the questionnaire was not translated into any of the local languages. The 
majority of the subjects were reasonably proficient in English language. Where there 
was need for interpretation, both medical and para-medical staff of the Cardiology Unit 
of the Department of Medicine of University of Abuja Teaching Hospital assisted. The 
questionnaire requested specific answers to date of birth, gender, occupation, 
background diagnosis of hypertension, background diagnosis of diabetes mellitus, 
history of angina pains, history alcohol consumption and history of smoking habits.  
 
3.3 Anthropometric Measurements 
The height and weight of the subjects were measured by the clinic nursing staff. Height 
and weight were measured with the participants standing, wearing indoor clothes with no 
shoes. Body mass index was calculated as weight in kilograms divided by the square of 
height in meters. Body surface area in meters2 (m2) was calculated as (0.0001) x 
(71.84) x (weight in kg)0.425 x (height in cm)0.725 
 
3.4 Conventional Blood Pressure Measurements 
Blood pressure measurements were obtained, according to standard guidelines, with a 
mercury sphygmomanometer (Accouson London). Systolic and diastolic blood pressures 
were measured by cardiologists at Korotkoff sounds I and V respectively. Blood 
pressure was measured at the right arm, three times after a 5-minute rest, with the 
patient in a sitting position, and the average of the three measurements was obtained. 












pressure, while mean arterial pressure was calculated as a third of diastolic blood 
pressure plus pulse pressure. 
 
 
3.5 Blood Measurements 
Apart from blood samples for fasting blood sugar, fasting lipid profile, electrolyte, urea 
and creatinine and full blood count, another 10mls was collected from each patient for 
NT-pro BNP assay. The blood was transfused into EDTA tubes and samples were 
immediately centrifuged,  plasma separated and then stored at -80 degrees Celsius until 
assayed. Samples were transported in dry ice and shipped to the Hatter Institute of 
Cardiovascular Research in Africa where the assay was carried out. 
 
3.5.1 Plasma NT-pro BNP Assay 
Plasma NT-pro BNP was measured by a standard electrochemiluminescence 
immunosssay. NT-pro BNP levels were measured from a banked aliquot from stored 
blood samples in triplicate. A sensitive and specific non-radioactive immunoluminometric 
(ILMA) assay based on competitive ligand binding was used. Stored samples were 
acidified with 1% trifluoroacetic acid (TFA) and loaded unto cartridges and eluted with 
1% TFA containing 60% acetonitrile. The samples were lyophilised in a centrifugal 
evaporator and re-dissolved in assay buffer consisting of 0.1mol/L sodium phosphate 
(pH 7.4), 0.1% Triton X-100 for the measurement. NT- pro BNP concentrations were 
determined blind to the clinical details of a subject. Figure 3.1 shows a picture of the NT-
pro BNP assay kit used for the study. 
 
3.5.2 Plasma ST2 Assay  
On patient enrolment, 20ml of venous blood was drawn into two separate tubes 
containing EDTA and Heparin, centrifuged and stored at -80 degrees Celsius. Soluble 
ST2 was measured by a sandwich double monoclonal antibody ELISA method, 
according to manufacturer’s instructions (Presage ST2 assay, Critical Diagnostics, New 
York, New York) (Dieplinger et al 2009). Figure 3.2 shows the picture of the Soluble ST2 
Assay kit which was used for the study. In brief, plasma samples and standards were 












conjugated anti-human ST2 antibody was added into the microwell and incubated. After 
a second of washing, the peroxidise substrate was added and the optical density at 
450nm was determined. A laboratory scientist, blinded to the clinical information, 
performed the ST assay. Although most reported studies refer to ST2 levels in serum, 
plasma ST2 was also increased in patients with acute heart failure (Dieplinger et al 
2010).  Furthermore, using the Presage ST2 assay as we did, soluble ST2 in frozen 
plasma samples has long-term stability for up to 18 months (Mueller et al 2008). 
 
 













Figure 3.2: Soluble ST2 Assay Kit 
 
3.6 Transthoracic Echocardiography 
Echocardiography was performed using a commercially available ultrasound system 
(IVIS-60) which is shown in figure 3.5. Subjects were examined in the left lateral 
decubitus position using standard parasternal, short-axis and apical views. Studies were 
performed according to the recommendations of the American Society of 
Echocardiography (Sahn et al 1978) by an experienced echocardiographer. In our 
echocardiography laboratory, the intra observer concordance correlation coefficient 
amongst the three cardiologists involved in the study ranges from 0.76–0.93, while that 
of the inter-observer concordance ranges from 0.82–0.95. Measurements were 
averaged over 3 cardiac cycles. The left ventricular measurements taken include inter-
ventricular septal thickness at end diastole (IVSd), the posterior wall thickness at end 
diastole (PWD), end diastolic diameter (EDD) and end systolic diameter (ESD). Left 
ventricular systolic function was calculated by Teichholz’s formula (13).  Figures 3.3 
shows the parastrernal long axis from one of the subjects. Left ventricular mass (LVM) 












(IVSTd + LVIDd + PWT d) 3 + 0.6g]. This has been shown to yield values closely related 
to necropsy left ventricular weight and that has good interstudy reproducibility (r=0.90). 
Relative wall thickness was calculated as 2 x posterior wall thickness / left ventricular 
internal dimension in diastole. Left ventricular hypertrophy was considered present when 
left ventricular mass index exceeded 49.2g/m2 in men and 46.7g/m2 in women 
(Devereux et al 1986, Palmieri et al 1999).  
The one-hundred and thirty-three subjects (133) without heart failure were divided into 
four geometric patterns (Kolo et al 2008) after transthoracic echocardiography. Subjects 
with normal LV mass index and relative wall thickness, less than 0.44, were considered 
to have normal geometry, while those with increased LV mass index and relative wall 
thickness greater than 0.44, were considered to have concentric hypertension. On the 
other hand, subjects had eccentric hypertrophy when there was  increased LV mass 
index but the relative wall thickness was less than 0.44, while subjects had concentric 
remodelling when there was normal left ventricular mass index but relative wall 
thickness greater than 0.44. Also in these one-hundred and thirty-three subjects without 
heart failure, electrocardiography data was analysed for LVH, and LVH was defined 
according to the classic criteria of Cornell and/or Sokolow-Lyon.    
The left and right atria areas were measured at end-ventricular systole when the atria 
chambers were at their greatest dimension, and with the bases of both atria at their 
greatest dimensions. Left ventricular inflow velocities were measured using pulsed-wave 
Doppler from the apical 4-chamber view, with the sample volume located between the 
tips of the mitral valve leaflet during ventricular diastole. Figure 3.6 and 3.7 show the 
apical four-chamber view of two of the subjects. Peak velocity of early rapid filling (E), 
peak velocity of late filling caused by atrial contraction (A) and the interval from peak of 
E wave to its extrapolation to the baseline or deceleration time (DT) were measured. 
The ratio of peak E-wave to A- wave was calculated. Diastolic function was categorized 
using mitral inflow and Doppler Tissue Imaging parameters. Grade 3 diastolic 
dysfunction or restrictive filling pattern was defined as E/A ratio greater than 2, with 
deceleration less than 130 milliseconds. Grade 1 diastolic dysfunction was defined as 
E/A ratio less than 1 and a deceleration time of 220 milliseconds, while grade 2 diastolic 
dysfunction or pseudonormal filling was diagnosed when deceleration time was greater 
than 220 milliseconds and the E/A ratio was between1-2. Right ventricular systolic 
function was assessed on echocardiography using M-mode recordings through the 
lateral tricuspid valve annulus for the purpose of measuring the tricuspid annular plane 












systolic excursion of the RV annular segment along its longitudinal plane, from a 
standard apical 4-chamber window. TAPSE represents longitudinal function of the right 
ventricle. It is inferred that the greater the descent of the base in systole, the better the 
RV systolic function. TAPSE (Figure 3.4) is usually acquired by placing an M-mode 
cursor through the tricuspid annulus and measuring the amount of longitudinal motion of 
the annulus at peak systole (Jurcut et al 2010). A TAPSE value less than 15mm denotes 
right ventricular systolic dysfunction (Ghio et al 2010). In the seventy-seven subjects 
with heart failure, right ventricular systolic pressure was calculated using the formula 
Right Ventricular Systolic Pressure (RVSP) = 4(TRV)2+Right Atrial Pressure(RAP). TRV 
reflects the difference in pressure between right ventricle and right atrium. The TRV was 
measured from the continuous wave Doppler of tricuspid regurgitant jet from apical four-
chamber or from the parasternal right ventricular inflow view if the regurgitant jet was 
eccentric. The RAP was estimated from the inferior vena cava (Lang et al, 2005) as 















Figure 3.3 Parasternal Long Axis View for one of the Hypertensive Subjects 
 
 














Figure 3.5:IVIS Ultrasound Machine that used for theStudy  
 
Figure 3.6 Apical four-chamber view of one of the hypertenive subjects with left 
ventricular hypertrophy 














Figure 3.7 Apical Four-Chamber View of one of the subjects with Hypertensive 
Heart Failure showing Dilated Cardiac Chambers 
 
Figure 3.8 Top View: Apical four-chamber view with the M-mode cursor at the 
tricuspid annulus. Bottom View: M-Mode image of the tricuspid annulus from 





















Table 3.1: Definition of Heart Failure according to the Recommendations of  
European Society of Cardiology 
Criteria I and II should be fulfilled in all cases 
Inferior Vena Cava 
Diameter 
Change with Respiration Estimated Right Atrial 
Pressure(mmHg) 
Small < 1.5cm Collapse 0 
Normal 1.5cm-2.5cm Decrease by > 50% 5 
Normal Decrease < 50% 10 
Dilated > 2.5cm Decrease by < 50% 15 
Dilated with Dilated 
Hepatic Veins  
No change 20 
 
Table 3.2 Estimation of Right Atrial Pressure from the Inferior Vena Cava 
 
 
3.7 Data Analysis 
Statistical Analysis  
SPSS software version 16.0 (SPSS Inc, Chicago, IL) and Medcal version 12.7 were 
used for statistical analysis. Continuous variables were expressed as mean±SD. 
Comparison of demographic, clinical, laboratory and echocardiographic parameters 
among the geometric patterns was performed by one-way ANOVA, with Sheffe’s post 
hoc test. Correlation coefficients were calculated by linear regression analysis with 
soluble ST2 and NT-pro BNP log-transformed to establish normality, and correlations 
I. Symptoms of heart failure (at rest or during exercise) 
                                      and 
II. Objective evidence (preferably by echocardiography) 
of cardiac dysfunction (systolic and/or diastolic) 
(at rest) and (in cases where the diagnosis is in doubt) 
                                     and 












between soluble ST2, NT-pro BNP and continuous demographic, clinical, laboratory and 
echocardiographic were evaluated by Spearman regression. Multivariate linear 
regression analyses were performed with log transformed soluble ST2 and NT-pro BNP 
concentrations as dependent variables, with inclusion of demographic, clinical, 
laboratory and echocardiographic parameters and biomarkers. A 2-tailed p value < 0.05 
was considered significant. Analyses of variation and operation characteristics were 
performed to determine the sensitivity and specificity of soluble ST2 and NT-pro BNP in 
differentiating the various spectrum of hypertension. To determine the diagnostic 
reliability of NT-pro BNP and ST2, the receiver operating characteristics (ROC) 
curve was calculated and the cut-off points that maximised sensitivity and 
specificity were selected. The validity indexes between the two tests were 


































4. 1 Demographic, Clinical and Laboratory Characteristics of Subjects 
4.1.1 Demographic, clinical and laboratory characteristics of the two-hundred and ten 
(210) subjects studied in Table 4.1.  
The mean age of the study cohort was 50.3±11.3 years. Subjects with hypertensive 
heart failure were the oldest, with a mean age of 53.0±11.9 years, while those with 
hypertension without LVH were the youngest, with a mean age of 47.3±11.0years.  
Subjects with hypertensive heart failure had the lowest weight of the three study groups 
with a body mass index of 25.4±4.5kg/m2, as against 27.6±6.6kg/m2 for subjects with 
hypertension and LVH (p-value=0.03). Hypertensives with left ventricular hypertrophy 
had the highest levels of mean arterial pressure and pulse pressure, while subjects with 
hypertensive heart failure had the lowest levels. There was no significant difference 
amongst the study populations in the levels of fasting blood sugar, fasting lipid profile, 


























Table 4.1 Demographic, Clinical and Laboratory Characteristics of Subjects 
P1=The p-value comparing hypertensive subjects with hypertensive subjects with left ventricular 
hypertrophy, P2= The p-value comparing hypertensive subjects with left ventricular wall hypertrophy and 
hypertensive heart failure,P3=The p-value comparing HT with HHF. BMI=Body Mass Index, FBS= Fasting 
Blood Sugar, TC=Total Cholesterol, LDLC=Low Density Lipoprotein Cholesterol, HDLC=High Density 















P2  P3 
AGE, years 47.3(11.0) 51.1(10.2) 0.05 53.0(11.9) 0.35 <0.002 
BMI, kg/m2 27.9(5.3) 27.6(6.6) 0.76 25.4(4.5) 0.03 <0.001 
FBS,  
mmol/L 
4.84(0.55) 4.85(0.60) 0.96 4.93(0.60) 0.45 0.35 
TC,   
mmol/L 
5.03(0.9) 4.70(1.11) 0.07 4.52(1.04) 0.36 <0.001 
LDLC, 
mmol/L 
3.20(0.8) 3.07(0.95) 0.36 2.95(0.84) 0.46 0.037 
HDL, 
mmol/L 
1.26(0.4) 1.20(0.33) 0.35 1.15(0.29) 0.36 0.031 
TG,  
mmol/L 
1.42(0.7) 1.45(1.04) 0.84 1.25(0.29) 0.52 0.375 
Creatinine,  91.60(21.9) 100.10(36.75) 0.10 104.73(27.71) 0.45 <0.001 
PCV 39.3(3.5) 39.2(4.2) 0.95 39.0(5.5) 0.78 0.68 
PP 64.1(15.0) 67.0(26.9) 0.43 54.3(17.4) <0.002 <0.000 
MAP 115.1(16.0) 120.6(26.7) 0.16 108.6(19.5) <0.001 <0.000 
NT-PRO 
BNP pg/ml 
341.0(95.8) 353.2(161.4) 0.68 501.8(199.8) <0.0002 <0.0001 
ST2ng/ml 14.5(4.9) 23.0(8.33) <0.0
01 












4.1.2 Clinical Features of the One-Hundred and Thirty Three Subjects without Heart 
Failure by the Four Left Ventricular Geometric Patterns in Table 4.2 
Subjects with concentric remodelling were the oldest (average age 56.1±8.4 years), 
versus subjects with normal geometry (average age of 46.3±10.8 years; p-value < 
0.004). Subjects with eccentric hypertrophy weighed the most (mean body mass index 
29.6 ±5.0kg/m2 versus those with normal geometry (BMI, 25.4±4.1kg/m2; p-
value<0.003). Subjects with concentric hypertrophy had the second largest BMI 
(28.7±5.4kg/m2) versus those with normal geometry (p-value=0.011). There was no 
significant difference in the blood pressure profiles of the four groups. 
 
4.1.3 Pattern of LV Geometry in the Subjects 
 Concentric remodelling was the most common form of geometry in 41.4% of cases, 
followed by eccentric hypertrophy in 30.8% of cases, then concentric remodeling in 
14.3% of cases and normal geometry in 13.5% of cases (Fig 4.1). Figure 4.2 shows the 
pattern of distribution of left ventricular geometry by gender. 42.4% of the female 
population had concentric hypertrophy, as against 40.4% of the male population. The 
male population, however, had higher percentages of subjects with eccentric and 
concentric remodeling in 32.8% and 14.9% respectively, as against 28.8% and 13.6% 
respectively in the female population. 
 
4.1.4 Clinical Profile of the seventy-seven Subjects with Hypertensive Heart Failure 
(Table 4.3) 
Table 4.3 shows the clinical profile of the seventy-seven subjects with heart failure. The 
mean age of the subjects was 53.8±13.2 years. There was no significant difference 
between the ages of the male and female subjects, nor was there a difference in the 
body mass index between male and female subjects. The men were more likely to 
smoke than the women (18.6% versus 2.5%, p-value< 0.0001), had better renal function 
with estimated glomerular filtration rate of 111.6 ± 41.4ml/min versus 78.3±17.0ml/min, 
p-value <0.0001 and were more likely to be diabetic (5.0% versus 1.6%, p-value 
<0.001). The women on the other hand were more likely to present with palpitations 
(57.7% versus 48.9%, p-value=0.02). Serum ST2 and NT-pro BNP levels were similar in 






















Age, years 46.3±10.8 49.3±11.0 45.9±9.8 56.1±8.4* 
Gender (%) F/M 15/12 42/40 28/33 13/15 
BMI, kg/m2 25.4±4.1 28.7±5.4* 29.6±5.0* 25.4±5.3 
SBP,  mmHg 151.1±20.0 158.5±27.2 148.0±22.4 145.3±19.0 
DBP, mmHg 94.4±11.0 99.2±15.8 94.8±15.0 92.9±13.0 
PP,  mmHg 56.7±14.1 59.3±20.9 53.2±14.7 52.3±12.9 
MAP, mmHg 118.1±15.5 122.4±21.9 128.8±16.2 123.3±13.9 
Soluble ST2 ng/ml 14.3±5.4 20.4±8.4** 17.8±8.3 16.2±2.9 
NT-pro BNP pg/ml 329.5±61.3 345±87.3 336.0±144.7 340±98.0 
Serum Creatinine 86.1±20.9 98.7±36.1 93.0±24.0 93.0±18.9 
Table 4.2 Clinical Features of the Four LV Geometric Patterns 
*= Significantly higher compared to normal geometry, **= p< 0.002, M=Male, F=Female, BMI=Body Mass 


















Parameters ALL(N=77) Male(N=54) Female± (N=23) P-value 
Age 53.8±13.2 53.8±15.8 51.7±13.6 0.56 
Smoking Habits 5(6.5%) 4(7.4%) 1(4.3%) <0.001 
DM 7(3.8%) 6(5.0%) 1(1.6%) <0.001 
Body Mass Index 24.30±7.0 24.2±7.6 24.5±5.9 0.86 
Palpitations 94(33.3%) 58(48.9%) 36(57.7%) 0.02 


















SBP 149.1±23.8 149.9±23.8 147.7±23.9 0.55 
DBP 98.1±13.9 98.2±13.9 97.9±13.9 0.92 
PP 55.8±16.2 56.4±16.8 54.7±15.0 0.52 
MAP 101.3±16.4 101.2±17.2 101.5±15.0 0.89 
FBS 5.3±2.2 5.2±2.0 5.4±2.4 0.58 
Total Cholesterol 4.2±1.2 4.1±.2 4.3±1.2 0.22 
LDL Cholesterol 2.7±0.9 2.6±1.0 2.8±1.0 0.14 
HDL Cholesterol 1.1±0.4 1.1±0.4 1.1±0.3 0.63 
Estimated GFR 101.5±38.8 111.6±41.4 78.3±17.0 <0.0001 
NT-pro BNP 501.7±199.8 513.0±208.5 478.7±184.7 0.58 
Serum ST2 112.9±78.7 100.1±60.4 134.4±98.3 0.26 
Table 4.3 Clinical Profile of the Subjects with Hypertensive Heart Failure  
DM=Diabetes Mellitus, SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, PP=Pulse 
Pressure, MAP=Mean Arterial Pressure, FBS=Fasting Blood Sugar, LDL=Low Density Lipoprotein, 



















Figure 4.1 Pattern of Left Ventricular Geometry in the Subjects 
 
















































4.2 Left Ventricular and Right Ventricular Geometric Changes Characterised by 
Echocardiography 
4.2.1 Echocardiographic Characteristics of all the Subjects studied (Table 4.4) 
Hypertensive subjects with LVH had significantly higher inter-ventricular and left 
ventricular posterior wall hypertrophy when compared with hypertensive subjects without 
left ventricular hypertrophy (p-value<0.001 and 0.001 respectively) and when compared 
with subjects with hypertensive heart failure (p-value<0.000 and 0.001). Hypertensive 
subjects with LVH also had higher left ventricular mass and left ventricular mass index, 
when compared with hypertensives without LVH and heart failure (p-value<0.001 
respectively). They however have a smaller left ventricular mass, whether indexed or 
not, when compared with hypertensive heart failure subjects (p-value<0.001). 
Hypertensive subjects without LVH and left ventricular heart failure had a significantly 
higher left ventricular ejection fraction when compared with hypertensives with LVH (p-
value of 0.02), and hypertensive heart failure subjects (p-value of< 0.001). Apart from 
the right atrial area, hypertensive heart failure subjects had a significantly higher 
chamber diameter. They also had the highest mitral ‘E’/’A’ ratio and the lowest tricuspid 
annular plane pulmonary systolic excursion value. 
 
4.2.2 Echocardiographic Characteristics of the four Geometric Patterns in One-Hundred 
and Thirty Three Subjects without Heart Failure in Table 4.5 
Subjects with concentric LVH, eccentric LVH and concentric remodelling had higher 
IVSTd and PWTd, compared to subjects with normal geometry, while subjects with 
concentric LVH and concentric remodelling had higher RWT compared to subjects with 
normal geometry. LVM index was highest in concentric LVH, followed by eccentric LVH. 
LV internal diameter in both diastole and systole were higher in all other geometric 
patterns relative to normal geometry. Subjects with concentric hypertrophy had the 
lowest LV ejection fraction versus those with normal geometry (70.7±18.6% versus 
76.7±18.6%; p-value= 0.02). Subjects with concentric remodeling had the smallest 
transmitral E/A (0.84±0.28 versus 1.1±0.29, p-value <0.008) versus those with normal 
geometry, while those with concentric remodeling had the largest deceleration time 















4.2.3 Echocardiographic Profile of the Seventy-Seven Subjects with Heart Failure 
by Gender in Table 4.6  
Male subjects had significantly more hypertrophy involving the inter-ventricular septal 
wall and a trend towards a thicker left ventricular posterior wall than female subjects. 
They also had a more dilated left ventricle, especially in diastole, than  female subjects. 
There was, however, no gender difference in the left ventricular mass indexed for height. 














Table 4.4   Echocardiographic Characteristics of all the Subjects 
HT=Hypertension without left ventricular wall hypertrophy, HT+LVH=Hypertension with left ventricular wall 
hypertrophy, HHF=Hypertensive heart failure, P1=p-value when HT and HT+LVH are compared and 
P2=p-value when HT+LVH and HHF are compared. P3= P-value when HT and HHF are 
compared.RVD=Right Ventricular Diameter in Diastole, IVSD=Inter-ventricular septal diameter in diastole, 
PWD= Posterior Wall Diameter in Diastole, EDD= End Diastolic Diameter, ESD= End Systolic Diameter, 
LVM= Left Ventricular Mass, ME= Early Mitral Inflow, MA= Late Mitral Inflow, LVEF = Left Ventricular 
Ejection Fraction, TAPSE= Tricuspid Annular Plane Systolic Excursion, DT=Decelaration time 
 
  
VARIABLE HT(83) HT+LVH(50) P1 HHF(77) P2  P3 
RVD 3.15(0.42) 3.10(0.43) 0.48 3.45(0.59) <0.0005 <0.000 
IVSD 0.92(0.15) 1.30(0.16) <0.0002 0.91(0.19) <0.0003 0.74 
PWD 0.91(0.13) 1.26(0.20) <0.0004 1.08(0.24) <0.0001 <0.000 
EDD 4.38(0.49) 4.37(0.95) 0.95 6.02(0.98) <0.0003 <0.000 
ESD 2.51(0.45) 2.72(0.95) 0.10 4.98(1.09) <0.0001 <0.000 
LVM 202.51(62.2) 296.1(151.8) <0.000 488.3(163.9) <0.0003 <0.000 
LVM/ HT2.7 52.6(15.6) 73.0(35.1) 0.000 113.9(40.2) <0.0004 <0.000 
LAA  18.1(12.5) 20.6(4.5) 0.29 23.5(6.9) <0.0001 <0.001 
RAA 14.8(3.0) 15.04(3.95) 0.72 21.6(7.1) 0.15 <0.000 
LVEF 76.8(14.0) 69.7(20.1) 0.02 32.2(13.6) <0.0002 <0.000 
ME 0.67(0.18) 0.66(0.18) 0.70 0.80(0.29) <0.003 <0.000 
MA 0.63(0.15) 0.67(0.20) 0.17 0.43(0.20) <0.0004 <0.001 
ME/MA 1.12(0.40) 1.1(0.43) 0.37 2.2 <0.0005 <0.000 
DT 177.6(39.5) 188.3(53.4) 0.20 120.6(59.4) <0.0006 <0.000 













Table 4.5 Echocardiographic Characteristics of the four Geometric Patterns  
*=Significantly higher compared to normal geometry (p<0.001), **=Significantly higher compared to 
concentric remodelling (p<0.001),RVD= Right Ventricular Diameter, IVSD=Inter Ventricular Septal 
Diameter in Diastole, Posterior Wall Diameter in Diastole, EDD= End Diastolic Diameter, ESD= End 
Systolic Diameter in Systole, RWT=Relative Wall Thickness, LVM= Left Ventricular Mass, HT=Height, 
LAA= Left Atrial Area, Right Atrial Area, LVEF= Left Ventricular Ejection Fraction, ME=Early Mitral Filling, 




















RVD 3.14±0.35 3.19±0.47 3.20±0.34 3.20±0.44 
IVSD 0.84±0.14 1.21±0.22* 0.97±0.18* 1.10±0.24* 
PWD 0.78±0.08 1.20±0.18* 0.91±0.13* 1.00±0.15* 
EDD 4.18±0.26 4.40±0.64* 4.80±0.71* 3.61±0.31* 
ESD 2.33±0.34 2.69±0.70* 2.80±0.77* 2.07±0.30* 
RWT 0.37±0.04 0.57±0.10* 0.38±0.04 0.57±0.12* 
LVM/HT 2.7       40.70±5.20 71.80±21.60* 65.40±32.30* 41.60±5.20 
LAA 19.30±4.83 20.70±3.80 18.70±3.30 14.00±3.20 
RAA 15.20±2.40 15.20±3.60 15.20±3.50 14.70±2.90 
LVEF 76.70±18.60 70.70±18.60* 75.20±15.10 80.10±11.40 
Mitral E/A  1.10±0.29 1.10±0.40 1.20±0.44 0.84±0.28* 
DT 158.90±22.30 191.20±50.0* 172.0±38.50 201.00±45.60* 












Parameters ALL(77) MALE(54) FEMALE(22) P-value 
RVD 3.4±0.6 3.5±0.6 3.2±0.5 0.22 
Left Atrium 4.6±0.9 4.6±0.9 4.5±0.8 0.17 
IVSD 1.1±0.3 1.1±0.2 1.0±0.3 0.03 
PWD 1.1±0.2 1.2±0.2 1.1±0.2 0.07 
EDD 5.8±1.1 5.9±1.1 5.5±1.1 0.04 
ESD 4.7±1.3 4.9±1.2 4.5±1.3 0.07 
LAA 24.5±7.0 24.5±6.7 24.4±7.5 0.95 
RAA 22.3±8.1 22.6±8.0 21.7±8.5 0.50 
LVMI 108.3±46.3 117.5±35.4 112.5±42.3 0.65 
LVEF 35.2±17.5 34.4±16.8 36.6±18.7 0.58 
ME 0.78±0.3 0.76±0.30 0.81±0.30 0.43 
MA 0.49±0.2 0.49±0.2 0.49±0.1 0.25 
ME/MA 2.2±1.3 2.0±1.2 2.2±1.4 0.96 
DT 143.2±80.6 143.7±85.1 142.2±72.2 0.22 
TAPSE 16.2±5.1 16.6±5.4 15.5±4.5 0.16 
TAPSE< 15mm 33(42.9%) 54(40.7%) 10(41.7) 0.18 
RVSP 31.4±10.5 31.4±10.4 31.3±10.5 0.97 




















4.3 NT-Pro BNP versus ST2 as Biomarkers in the Hypertensive Cohort 
4.3.1 Concentrations of Plasma NT-pro BNP in the Hypertensive Cohort  
Figure 4.3 shows the different concentrations of plasma NT-pro BNP in the hypertensive 
cohort. There is no significant difference in the plasma concentrations of log transformed 
NT-pro BNP between the hypertensive subjects and subjects with hypertensive LVH, but 
there is a significant difference when hypertensive subjects, with or without left 
ventricular hypertrophy, are compared with those with heart failure. Figure 4.4 shows in 
receiver operation curve the differentiation of subjects with hypertension without LVH 
(HT) from those with heart failure (HHF), using NT- pro BNP. The sensitivity of NT-pro 
BNP in differentiating these two categories of subjects is 73.7%, while the specificity is 
57.1%, with a cut-off value of 447.6pg/ml. The area under the curve (AUC) is 0.709, 
95% confidence interval (CI) is 0.600-0.802 and p-value < 0.0002. Figure 4.5 similarly 
shows the receiver operation curve which differentiates subjects with hypertension and 
LVH (HTLVH) from hypertensive heart failure (HHF). The sensitivity of this differentiation 
is 49% and specificity is 83.3%. The area under the curve is 0.640, 95% confidence 
interval is 0.541-0.731 and p-value is 0.011. 
 
Figure 4.3: Box plot showing the different Concentrations of Serum NT-pro BNP in 
the Hypertensive Cohort 













Figure 4.4: Receiver Operation Curve showing differentiation of Hypertension 
without LVH from Hypertensive Heart Failure 
 
Figure 4.5: Receiver Operation Curve showing differentiation of Hypertension with 














4.3.2 Clinical and Echocardiographic Correlates of NT-pro BNP  
Pearson correlation analysis of clinical and echocardiographic variables with log 
transformed NT- pro BNP in the study population is shown in table 4.7. NT-pro BNP was 
significantly associated with left ventricular ejection fraction (p-value=0.01), but not with 
tricuspid annular plane systolic excursion. It was also significantly correlated with age (p-
value< 0.04), pulse pressure and mean arterial pressure (p-value=0.002 respectively), 
systolic blood pressure (p-value=0.007), serum creatinine (p-value=0.038) and right 
atrial area. There was no significant correlation between NT-pro BNP with body mass 
index, right ventricular diameter in diastole, inter ventricular septal wall thickness in 
diastole, posterior wall diameter in diastole, left  atria area, left ventricular mass index , 
transmitral E/A ratio, deceleration time and tricuspid annular plane systolic excursion  
 
4.3.3 Independent Variables of NT-pro BNP 
 In multivariate linear regression analysis (Table 4.8) independent predictors of NT-pro 
BNP in the study population include left ventricular ejection fraction (t=2.11; p=0.037), 
















Table 4.7 Clinical and Echocardiographic Correlates of NT-pro BNP  
IVSDd= Interventricular Septal Diameter in diastole, PWDd=Posterior Wall Diameter in diastole, 
LVIDs=Left Ventricular Internal Diameter in systole, RVD=Right Ventricular Diameter in diastole, LAA=Left 
Atrial Area, RAA=Right Atrial Area, TAPSE=Tricuspid Pulmonary Systolic Excursion, EF=Ejection 
Fraction, ME=Early Mitral Filling, A=Atrial or late mitral filling 
 
Table 4.8 Independent Co-variants of NT-pro BNP 
Parameters Coefficient of association (r) p-value 
Age 0.17 0.04* 
BMI -0.07 0.40 
Pulse Pressure 0.26 0.002* 
Mean Arterial Pressure 0.26 0.002* 
IVSDd 0.17 0.05 
PWDd 0.08 0.36 
LVIDD 0.16 0.05 
LVIDS 0.21 0.01* 
RVD 0.09 0.31 
LAA 0.02 0.80 
RAA 0.20 0.04* 
LVM/HT2.7  0.09 0.30 
Left Ventricular EF -0.21 0.01* 
Mitral  E 0.02 0.79 
Mitral A 0.12 0.15 
Mitral E/A Ratio 0.08 0.35 
Deceleration Time 0.14 0.09 
TAPSE -0.23 0.15 
Parameters t p-value 
Left Ventricular Ejection Fraction 2.1 0.03 
Left Ventricular Internal Diameter in Diastole 2.2 0.03 













4.3.4 Concentrations of Soluble ST2 in the Hypertensive Cohort 
There was significant difference in serum soluble ST2 levels in the study cohort, with 
HHF subjects having significantly higher concentrations of serum soluble ST2, 
compared with subjects with HTLVH (134.7±57.3pg/ml versus 23.0±8.33pg/ml, p-value< 
0.0001). On the other hand, subjects with HTLVH had higher concentrations when 
compared with HT subjects (23.0±8.3pg/ml versus 14.5±4.9 pg/ml) as shown in figure 
4.6. The sensitivity and specificity of differentiating HT from HHF were 82.4% and 100% 
respectively, with a cut-off value of 25.0ng/ml, as shown in the receiver operation curve 
(ROC) in figure 4.7. The area under the curve is 0.98, confidence interval is 0.89-0.99 
and p-value < 0.0001. On the under hand, the sensitivity of distinguishing HT from 
HTLVH were 87% and 56.7% respectively, with a cut-off value of 14.45ng/ml, as shown 
in figure 4.8. The area under the curve is 0.72, 95% confidence interval is 0.57-0.85 and 
p-value is 0.004. Similarly, the sensitivity and specificity of distinguishing HTLVH from 
HHF were 76.5% and 100% respectively with a cut-off value of 38.0ng/ml, as shown in 
figure 4.9. The area under the curve (AUC) is 0.90, 95% confidence interval is 0.79-
0.97and p-value< 0.0001.  
 














               Figure 4.7                                   Figure 4.8                                  Figures 4.9 
Figures 4.7, 4.8 and 4.9: Receiver Operation Curve Showing the differentiation of 
the various Hypertensive Cohorts using Soluble ST2 
 
4.3.5 NT-pro BNP versus ST2 in distinguishing Hyp rtension with or without LVH 
from Hypertensive Heart Failure 
Figures 4.10 and 4.11 show the comparison between soluble ST2 and NT-pro BNP in 
differentiating hypertension, with and without LVH, from hypertensive heart failure. 
Figure 4.10 shows that soluble ST2 is a better biomarker in differentiating HT from HHF 
with the difference between the areas of 0.30, 95% confidence interval of 0.146-0.452 
and p-value < 0.0001.Figure 4.11 also shows that soluble ST2 is a better biomarker in 
differentiating HTLVH from HHF, with a difference between the areas of 0.27, 





Figure 4.10: Comparison of ROC Curve of NT-pro BNP and ST2 in differentiating 
HT from HHF.Difference between areas under the curve (AUC)=0.30 and p-
value<0.0001 
 
Figure 4.11: Comparison of ROC Curve of NT-pro BNP and ST2 in differentiating 
HTLVH from HHF. The differences in area under the curve (AUC)= 0.27 and p-
value<0.01 
4.3.6 Univariate Association between Log Transformed Soluble ST2 and some 
Clinical and Echocardiographic Parameters 
Table 4.10 shows the univariate association between log transformed ST2 and clinical, 
laboratory and echocardiographic parameters. There was significant correlation between 
serum soluble ST2 and body mass index, inter-ventricular septal wall thickness in 










































diastole, posterior wall thickness in diastole, left ventricular internal diameter in diastole 
and systole, right atrial size, left ventricular mass index, left ventricular ejection fraction 
and transmitral E/A ratio. There was no correlation with left atrial area, and no 
correlation with blood pressure profiles. Of note, one of the most statistically significant 
associations was with left ventricular mass indexed for hypertension. 
Parameters  R  PValue  
Age 0.09 0.39 
BMI 1.6 0.16 
Pulse Pressure 0.26 0.02 
Mean Arterial Pressure 0.23 0.04 
IVSD 0.12 0.27 
PWD 0.16 0.14 
EDD 0.58 <0.0003 
EDS 0.61 <0.0004 
RVD 0.28 <0.008 
LAA 0.48 <0.0004 
RAA 0.46 <0.0005 
LVM/ HT 2.7  0.57 <0.0001 
Left Ventricular EF -0.60 <0.0002 
Mitral  E 0.42 <0.0005 
Mitral A 0.26 0.02 
Mitral E/A Ratio 0.43 <0.0006 
Deceleration Time 0.48 <0.0004 
TAPSE 0.15 0.20 
NT-pro BNP 0.41 <0.0003 
Table 4.9: Univariate Association between Log Transformed Soluble ST2 and some 
Clinical and Echocardiographic Parameters 
RVD=Right Ventricular Diameter in Diastole, IVSD=Inter-Ventricular Diameter in Diastole, 
PWD=Posterior Wall Diameter in Diastole, EDD=End-Diastolic Diameter, ESD=End-Systolic Diameter, 
LVM=Left Ventricular Mass, LAA=Left Atria Area, RAA=Right Atria Area, EF=Ejection Fraction, 
ME=Early Mitral Filling, MA=Late Mitral Filling, TAPSE=Tricuspid Annular Plane Systolic Excursion, 








4.3.7 Multivariate Analysis of Independent Co-variants of Log Transformed 
Soluble ST2 in Table 4.11 
In a multivariate analysis (table 4.8), the independent co-variants of serum soluble ST2 
concentrations were found to be LV ejection fraction (beta=0.61; p<0.0002), LV mass 
indexed for height 2.7 (beta=0.56, p<0.0001), left internal diameter in systole (beta=0.61, 
p<0.0004) and pulse pressure (beta=2.5, p=0.01).  
 




4.4 Differentiation of Left Ventricular Geometric Patterns and Right Ventricular 
Function by NT-Pro BNP and ST2 and Echocardiography 
4.4.1 Left Ventricular Geometric Pattern and Cardiac Biomarkers  
Subjects with concentric hypertrophy had the highest concentrations of soluble ST2 
(mean 20.4±8.4pg/ml) versus subjects with normal geometry (14.3±5.4pg/ml; p-
value=0.002), as shown in table 4.5. The sensitivity of soluble ST2 in differentiating 
concentric hypertrophy from normal geometry was 68.2% and the specificity was 88.2% 
at a cut-off mark of 17.4ng/ml (Fig 4.12). There were no significant differences in the 








Left Ventricular Ejection Fraction (%) 0.56 <0.0001  
Left Ventricular Internal Diameter in Systole 0.61 <0.0003 
Left Ventricular Mass Index for HT 2.7 0.56 <0.0001 







Figure 4.12: Receiver Operation Curve Showing the Sensitivity and Specificity of  
Soluble ST2 in Differentiating Concentric Hypertrophy from Normal Geometry  
 
4.4.2 Diagnostic Accuracy of ST2 compared with Electrocardiography in Detecting 
LVH in Hypertensive Subjects without Heart Failure 
Table 4.11 shows that 8(16%) of subjects with echocardiographic diagnosis of LVH had 
LVH using electrocardiographic criteria of Cornell and/or Sokolow-Lyon, while 4(4.8%) of 
those without LVH had LVH on ECG. Table 4.13 compares the sensitivity, specificity, 
positive and negative predictive values of soluble ST2 and ECG in diagnosing LVH. We 
found that the diagnostic accuracy of soluble ST2 was greater than that of 
electrocardiography study as evidenced by higher sensitivity and negative predictive 
value for this marker. 
  
 4.4.3 The Relationship between TAPSE and various echocardiographic and 
laboratory parameters.  
Table 4.12 shows the relationship between right ventricular systolic function, as 
assessed by TAPSE, and various echocardiographic and laboratory parameters. Left 
atrial diameter, areas of both atria, left ventricular end-diastolic and end-systolic 
VARIABLE












ity  Sensitivity: 68.2
 Specificity: 88.0
 Criterion : >17.38
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diameters, left ventricular mass index, right ventricular systolic pressure, left ventricular 
ejection fraction and transmitral E/A ratio were found to correlate significantly with 
TAPSE. There was, however, no significant correlation between TAPSE and cardiac 
biomarkers.  
 
4.4.4 The relationship between right ventricular systolic pressure and cardiac 
biomarkers  
Table 4.13 shows the relationship between right ventricular systolic pressure and 
cardiac biomarkers. Both serum ST2 and NT-pro BNP were significantly correlated with 


























Table: 4.11: Biomarkers, Electrocardiographic and Echocardiographic  
Characteristics of the subjects without Heart Failure  
RVD=Right Ventricular Diameter, IVSD=Inter-ventricular Septal Thickness in Diastole, PWD=Posterior 













VARIABLE HT(83) HT+LVH(50) P1 
RVD 3.15(0.42) 3.10(0.43) 0.48 
IVSD 0.92(0.15) 1.30(0.16) <0.0002 
PWD 0.91(0.13) 1.26(0.20) <0.0004 
EDD 4.38(0.49) 4.37(0.95) 0.95 
ESD 2.51(0.45) 2.72(0.95) 0.10 
LVM 202.51(62.2) 296.1(151.8) <0.000 
Soluble ST2(ng/ml) 14.5(4.9) 23.0(8.33) <0.001 
NT-PRO BNP(pg/ml) 341.0(95.8) 353.2(161.4) 0.68 






Table 4.12: Indexes of Diagnostic Validity for Electrocardiography and ST2 in Left  
Ventricular Hypertrophy 

















 ECG%  (95% CI) ST2(>14.45ng/ml)% 95% CI P-value 
Sensitivity 16.0(8.6-23.8) 87.0(75.8-96.4) <0.001 
Specificity 95.2 (83.8-99.7) 56.7(48.7-65.7) <0.001 
PPV 51.6(19.9-82.4) 40.1(28.7-52.3) <0.001 




Table 4.13: Relationship between TAPSE and various echocardiographic and 
laboratory parameters. 
Parameters Pearson Correlation P-value 
Left Atrial Diameter -0.54 <0.0001 
EDD -0.47 <0.0001 
ESD -0.55 <0.0001 
LVM/HT2.7 -0.34 <0.0001 
LVEF 0.60 <0.0001 
Mitral E/A -0.39 <0.0001 
Left Atrial Area -0.24 0.02 
Right Atrial Area -0.44 <0.0001 
RVSP -0.74 <0.0001 
RVD -0.035 0.77 
Soluble ST2 0.04 0.68 
NT Pro BNP 0.000 0.99 
EDD=End-Diastolic Diameter, ESD= End-Systolic Diameter, LVM=Left Ventricular Mass, HT-Height, 
LVEF=Left Ventricular Ejection Fraction, E=Early Filling, A=Atrial Filling, RVSP= Right Ventricular Systolic 
Pressure, RVD=Right Ventricular Diameter  
                                                           
                                                        
                                                               
 











                                                            Summary of Results 
 
   










Soluble ST2 is a better biomarker 
than NT-Pro BNP in differentiating 
the various spectrum of 
hypertensive heart disease
Soluble ST2 is not only affected by 
LV remodelling but also by right 
ventricular remodelling 
Concentric hypertrophy has the 
greatest impact on the 
concentration of soluble ST2  of all 
geometric patterns in 
hypertensives without heart 
failure











A large proportion of the 
hypertensive heart failure subjects 
had right ventricular systolic 
dysfunction on presentation
Amongst the subjects with 
hypertensive heart failure, the 
male subjects had more dilated 
left ventricule compared to the 
female subjects 
Amongst the hypertensive group 
without heart failure, those with 
LVH had worse LV systolic function 






5.1 Characteristics of the study Population  
This study documented the clinical profile of two-hundred and ten (210) hypertensive 
subjects, with or without heart failure, presenting to a tertiary institution in Abuja, Nigeria. 
We found the patients to be middle-aged, with a mean age of 47.3±11.0 years. This is in 
keeping with previous studies which show that the complications of hypertension tend to 
occur more often, and at an earlier age, in black populations compared to Caucasians 
(Cruickshank JK et al 1980, Shulman NB et al 1991, Onwuanyi A et al 1998). Our 
demographic data also show that that the subjects with hypertensive heart failure were 
much younger, with a mean age of 53.0±11.9 years, compared to the developed 
countries where heart failure is a disease of the elderly, with an average age of 76 years 
(Goldberg et al 2007; Vasan et al 1999). Hypertensive heart failure presenting in a 
relatively young cohort in this Nigerian population is a further reflection of the 
presentation of the complications of hypertension at an early stage. Long distances and, 
often, lack of funding to cover the travel fare, are important aspects of late presentation 
to health care (Mocumbi et al 2012). This presentation of hypertensive heart failure at a 
relatively early age has the potential to undermine national productivity, as a 
consequence of the number of active life years lost by the most active workforce of the 
population, with important consequences to the entire family.  
The three hypertensive groups were overweight, with a mean body mass index ranging 
from 25.4kg/m2 to 27.9lg/m2. The subjects with heart failure had the lowest body mass 
index of 25.4kg/m2, which is in keeping with previous reports, as heart failure is often 
associated with weight loss (Pocock et al 2008). The group with heart failure also had 
the lowest mean arterial blood pressure level and this can, in part, attributed to the fact 
that these subjects often present with dilated left ventricular chambers and poor systolic 
function, thereby reducing cardiac output. Even though the average creatinine level was 
normal, as subjects with elevated creatinine were excluded from the study, the cohort 
with heart failure had significantly higher serum creatinine compared to hypertensive 
subjects without LVH. The possible explanation for this is both congestion and low renal 
perfusion from poor left ventricular systolic function in these subjects (Guglin et al 2011). 
Anaemia was not a common problem in this hypertensive cohort, with a mean packed 
cell volume of 39.0% in the study population. This can be partly explained by the fact 
that subjects with chronic kidney disease were excluded from this study as it is a well 
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known fact that chronic kidney disease is the most common cause of anaemia in 
hypertensive subjects in sub-Saharan Africa (Alebiosu CO et al 2006). Subjects with 
diabetes mellitus were also excluded from the study, accounting for the mean fasting 
blood sugar of 4.8mmol/l seen in our study cohort. Lastly, the prevalence of smoking in 
our heart failure subjects was considerably lower, compared to that in the developed 
nations and even lower in our female population, as shown in table 4.3. This is likely to 
have contributed to the lower prevalence of coronary artery disease in our environment. 
 
5.2 Left and Right Ventricular Changes Characterised by Echocardiography 
In this study, both the left and right ventricular structure and function were assessed. We 
found that 37.6% of the one-hundred and thirty-three subjects without heart failure had 
echocardiographic LVH, in keeping with previous studies in black hypertensive subjects 
For example, Post et al (Post et al 2003) found an echocardiographic prevalence of 30% 
among 309 hypertensive African American men aged 18-54 years while Koren et al 
(Koren et al 1993) reported a prevalence of 41% in 47 black subjects with uncomplicated 
hypertension. Subjects with hypertensive heart failure had significantly more dilated left 
atrium and left ventricle, when compared with subjects without heart failure. They also 
had significantly more dilated right cardiac chambers. The larger right-sided cardiac 
chambers in these subjects implies that a significant proportion of our heart failure 
patients already have right ventricular dysfunction on presentation as right atrial and 
right ventricular sizes have been reported as markers of right ventricular dysfunction 
(Graspa J et al 2012, Ghio S et al 2010). This may, therefore, partly explain the poor 
prognosis of hypertensive heart failure in sub-Saharan Africa (Isezuo AS et al 2000) as it 
will well known that ventricular size and function are prognostic markers in left-sided 
heart failure (Dini FL et al 2012). There is, therefore, the need to investigate the effect of 
right ventricular dysfunction on prognosis in our hypertensive heart failure subjects.  As 
expected, our cohort with heart failure had the worst left ventricular systolic function. We 
also found that subjects with HTLVH had significantly lower left ventricular ejection 
fraction, when compared with HT subjects which had been previously reported in 






5.3 BNP versus Soluble ST2 as Biomarkers in the Hypertensive Cohort 
The results of this study have  shown that even though serum ST2 and NT-pro BNP can 
be very useful in distinguishing subjects with HTLVH from those with HHF, in keeping 
with a previous study (Talwar et al 2000), it is only serum ST2 that differentiates HT from 
HTLVH. These have been shown in figures 4.3 and 4.6. The significantly higher 
concentrations of serum soluble ST2 in subjects with HTLVH compared to those with 
HT, and significantly higher concentrations of plasma ST2 in HHF subjects compared to 
HTLVH subjects, is not surprising as serum ST2 concentration correlates well with wall 
tension and LV ejection fraction, both of which are caused by hypertensive LVH and 
hypertensive heart failure respectively (Sabatine et al 2008; Diez et al 2008). At a 
molecular level, the varying degree of mechanical strain imposed on cardiac myocytes 
(Weinberg et al 2002) by these three conditions could be postulated to explain the links 
between the ST2 concentrations and the clinical pictures. The mechanism of secretion 
of ST2 in hypertensive heart disease spectrum could thus be linked to cardiomyocyte 
hypertrophy and fibrosis which are prominent features of hypertensive LVH, and 
apoptosis which is a prominent feature of hypertensive heart failure (Sanada et al 2007; 
Seki et al 2009). Plasma ST2 correlated well with LV mass index in our hypertensive 
cohort, with LV mass indexed for height being an independent predictor of the 
concentration of serum soluble ST2 (beta=0.56, p-value<0.0001), as shown in table 
4.11, but there was no significant correlation between NT-pro BNP and LV mass index 
(r=0.09, p-value=0.30), as shown in table 4.8. In a previous study in hypertensive 
subjects which used serum NT-pro BNP as a biomarker, there was a poor correlation 
between LV mass index and NT-pro BNP(13). Thus, ST2 may be a better biomarker in 
differentiating the various components of the spectrum of HT, HTLVH and HHF from 
each other. Also on head-to-head comparison using differences in areas under the 
curve, ST2 was found to be a better biomarker than NT-pro BNP in differentiating HT 
from HHF(p,0.0001) and HTLVH from HHF(p=0.01), as shown in figures 4.10 and 4.11. 
LV ejection fraction was a predictor of plasma concentrations of soluble ST2. Even 
though it is known that LV ejection fraction is a strong predictor of serum soluble ST2 
concentration (Shah et al 2009), our study is the first to demonstrate this relationship in 
a cohort of hypertensive subjects. Therefore, the diagnostic role of serum soluble ST2 is 
not limited to heart failure of only ischemic aetiology, but may also extend across all 
types of heart failure. Since LV ejection is a strong prognostic factor in heart failure 
(Sanada et al 2007;Karaye et al 2008), our data therefore suggest that  plasma ST2 
could be a good prognostic marker of heart failure in hypertensive subjects.  
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A second important finding was that ST2 correlated well with right atrial area (r=0.46, p-
value <0.0001) and less significantly with right ventricular diameter (r=0.26, p-
value=0.0008), while NT-pro BNP correlated weakly with right atrial area (r=0.2, p-
value=0.04) and did not correlate significantly with right ventricular diameter.  
Daniel (Daniel et al 2010) had previously shown that serum soluble ST2 correlates well 
with the size of the right ventricle and is a predictor for mortality. Our results in this study 
have demonstrated a relationship between soluble plasma ST2 with ventricular sizes in 
a population of hypertensive subjects with or without heart failure. 
We also showed an association between serum soluble ST2 and all the 
echocardiographic LV diastolic function parameters, in keeping with the findings of Shah 
(Shah et al 2011), who found an association between ST2 and echocardiographic LV 
diastolic parameters. They found serum ST2 to be a strong predictor of mortality in 
patients with acute dyspnoea, especially in those with preserved LV ejection fraction. 
Therefore, plasma ST2 is not only correlated with systolic function, but also with diastolic 
function in a cohort of our hypertensive subjects. On the other hand, there was no 
significant correlation between NT-pro BNP and all indices of diastolic function assessed 
in our study cohort, similar to previous studies (Fruhwald et al 1999). 
In addition, levels of NT-pro BNP correlated with age (Redfield et al 2002) and serum 
creatinine levels as in previous reports (Sriswasdi et al 2010). ST2 levels did not, 
however, correlate significantly with either age or serum creatinine, which is another 
reason ST2 might be a better marker than NT-pro BNP, as it is less likely to be affected 
by confounders such as age and renal dysfunction.   
Furthermore, we found a correlation between serum soluble ST2 levels and serum NT-
pro BNP, with a correlation coefficient of 0.41 and a p <0.0002. This is similar to the 
findings of Shah et al (34), who found a correlation (p = 0.009) between serum soluble 
ST2 and serum NT-pro BNP. 
Overall, our study has shown that serum ST2 is a very useful biomarker in differentiating 
the various spectrum of hypertension. We have also shown that serum ST2 does not 
only complement the role of NT-pro BNP in differentiating the various spectrum of 
hypertension, but might be a better biomarker than NT-pro BNP in this regard.  Our 
findings will assist in distinguishing the three prognostic patterns of uncomplicated 
hypertension from two of its major cardiac complications, and may also become useful in 
the choice of specific antihypertensive medications. It is well known that medication such 
as angiotensin converting enzyme inhibitors (Shimamoto et al 1996), angiotensin 
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receptor blockers (Cuspidi et al 1996), beta-1-selective blockers (Cifkova R et al 1987) 
and long-acting calcium channel blockers (Nalbantgil et al 1996) have been found to 
regress the LVH, while thiazide diuretic monotherapy which is a common prescription 
pattern in our setting (Kazeem et al 2005), has not been found to do so (Strauer et al 
1985). In a meta-analysis  of eighty (80) trials (shown in figure 5.1) with one-hundred 
and forty-six (146) treatment arms and a study population of  3767, and 17 placebo arms 
with a population of  346, after adjusting for treatment duration and change in diastolic 
blood pressure, there was significant difference(p=0.004) in left ventricular mass 
regression among anti-hypertensive medication classes. Angiotensin II receptor 
blockers(ARBS) reduced LVM by 13%, calcium channel blockers (CCBs) by 11%, 
angiotensin converting enzyme inhibitors(ACEIs)  by 10%, while diuretics and beta-
blockers only reduced LVM by 8% and 6% respectively. It was concluded that in pair 
wise comparisons, ARBs, CCBS and ACEIs were more effective in reducing LVM than 
beta-blockers and diuretics.  
Since the diagnosis of ischemic heart disease was made clinically using history and 
electrocardiography, with no myocardial perfusion imaging and coronary angiography 
performed, it is possible that subtle coronary artery disease might have been missed. 
However, with the low prevalence of clinical myocardial infarction and the high 
cost of myocardial perfusion and coronary imaging in this environment we did not 
think it was justifiable for these subjects to have these investigations. 
Serum soluble ST2 does not only complement the role of NT-pro BNP as a biomarker in 
differentiating hypertension itself from two of its major cardiac complications, but it is an 
excellent biomarker in this regard. The usefulness of soluble ST2, therefore, extends 
beyond ischemic heart disease and cardiomyopathies to hypertensive heart disease. 
 
5.4 Differentiation of Left Ventricular Geometric Patterns by NT-pro BNP and ST2 
Concentric hypertrophy was the most common geometric pattern in our study cohort 
(Figure 4.1), and just slightly more common in the female population, compared to the 
male population (42.4% versus 40.4%), as shown in figure 4.2. This is similar to 
previous findings in Nigerian hypertensive subjects (Kolo PM et al 2008, Karaye KM et al 
2008). Gender-specific differences in left ventricular geometric pattern have recently 
been demonstrated by Rider et al. in obese subjects, who found that obese men have 
predominantly concentric hypertrophy, whereas obese women exhibit both eccentric and 
concentric hypertrophy (Rider OJ et al 2013). The higher prevalence of concentric LVH, 
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compared to other geometric patterns, is an important finding as the prevalence of death 
and cardiovascular complications associated with hypertension is higher in hypertensive 
patients with concentric hypertrophy than in other groups, including patients with 
eccentric hypertrophy (Okin PM et al 2002). We found that plasma ST2 levels were 
increased in hypertensive patients with all three patterns of abnormal LVH geometry, as 
compared to normal geometry, but highest in those with concentric hypertrophy (Table 
4.2) despite comparable blood pressures and left ventricular mass index values. These 
results suggest that there is not only a relationship between hypertensive LVH and 
soluble ST2, but that this relationship is in keeping with the particular geometric pattern. 
Therefore, measurement of soluble ST2 could be useful in detecting the particular 
geometric abnormalities of LVH, thereby facilitating risk stratification.  
More specifically, we found significant correlations between plasma ST2 and left 
ventricular mass index, inter-ventricular septal wall thickness in diastole, posterior wall 
thickness in diastole, left ventricular internal diameter in diastole and systole, right atrial 
size, left ventricular mass index, left ventricular ejection fraction and transmitral E/A 
ratio. The correlation of ST2 with left ventricular wall thickness and chamber sizes is a 
reflection of the mechanism of secretion of ST2 which is related to mechanical stress 
(Townsend MJ et al 2000). The correlation between left ventricular ejection fraction and 
transmitral E/A ratio is an indication that serum soluble ST2 levels are not only markers 
of left ventricular systolic function, but may also be a marker for left ventricular diastolic 
function in hypertensive heart disease. The correlation with right atrial area (a marker for 
right ventricular function) implies that serum soluble ST2 may be related to right 
ventricular function.  
We also observed that our hypertensive subjects with concentric hypertrophy had the 
lowest left ventricular ejection fractions (Table 4.5), compared with those with normal 
geometry, further supporting the finding that concentric hypertrophy carries the worst 
prognosis of the geometric patterns in hypertension (Okin PM et al 2002). Lower left 
ventricular ejection fraction is an independent marker of worse prognosis in hypertensive 
heart disease (Weir RAP et al 2010). Toshio et al. (Takeda T et al 1995) had earlier 
reported higher levels of plasma NT-pro BNP, which is another biomarker that correlates 
well with serum soluble ST 2 in hypertensive subjects with concentric LVH, compared to 
other geometric patterns. In our study, even though subjects with concentric hypertrophy 




Our findings suggest that the soluble ST2 level is not only affected by ischemic heart 
disease, but extends to the particular geometric pattern in hypertension.  Soluble ST2 
may, therefore, be a new method of studying myocardial geometry, not only in ischemic 
heart disease but in hypertension, and may be a future biomarker for assessing the full 
impact of hypertension on the myocardium.  
 
5.5 Diagnostic Accuracy of ST2 compared with Electrocardiography in Detecting LVH in 
Hypertensive Subjects without Heart Failure 
Since electrocardiography is the most common means of diagnosing left ventricular 
hypertrophy and with previous findings that it lacks sensitivity (Levy D et al 1990), we 
decided to compare the sensitivity of soluble ST2 and ECG in detecting LVH in our one-
hundred and thirty-three hypertensive cohorts without heart failure. We found that the 
diagnostic accuracy of soluble ST2 was greater than that of electrocardiography studies, 
as evidenced by higher sensitivity and negative predictive value for this marker, as 
shown in table 4.13. There is the need for this aspect of the study to be carried out in a 
larger population of hypertensive subjects to validate this point. 
 
5.6 Cardiac Enzymes and Echocardiography in the Assessment of Right Ventricular 
Function in the Heart Failure Group  
Right ventricular function is influenced by both intrinsic factors, such as contraction of 
the right ventricular myocardium, and by extrinsic factors, such as preload, afterload, left 
ventricular function, contractile function of the inter-ventricular septum, the pericardium 
and right coronary artery perfusion(Devereux RB et al 1986,). Furthermore, it has been 
said that left ventricular failure is the most common cause of right heart failure (Palmieri 
V et al 1999). Conversely, the right ventricle can influence left ventricular filling through 
diastolic ventricular interaction (Atherton JJ et al.  1997). This study has shown the 
influence of hypertensive heart failure on right ventricular function. Although 
hypertensive heart failure has been previously identified as the most common singular 
cause of left-sided heart failure (Kizer JR et al 2004, Drazner MH et al 2005, Sharp A et 
al 2008, Damasceno A et al 2012,  Kingue S et al 2005, Commerford P et al 2006, Oyoo 
GO et al 2006, Amoah AGB et al 1999, Karaye KM et al 2008, Ojji DB et al 2009, 
Damasceno A et al 2007), the effect on the right ventricle is not well reported.  Our 
study, therefore, is one the first to report the effect of hypertensive heart failure on right 
ventricular function in the sub-Saharan African population. 
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We found right ventricular systolic dysfunction in 33 (42.9%) of the seventy-seven (77) 
subjects that were studied. The high prevalence of right ventricular dysfunction in our 
hypertensive heart failure cohort might partly explain the poor prognosis that is found in 
our hypertensive heart failure subjects, as it is a well known fact that right ventricular 
systolic dysfunction is a poor prognostic factor in heart failure (Jurcut  et al 2010,Hines R 
et al 1986, Dini et al 2012). There is a need, therefore, to pay more attention to right 
ventricular function which has been previously neglected in our hypertensive heart 
failure subjects. The affectation of right ventricular function by left heart failure has been 
linked to ventricular interdependence (Di Salvo TG et al 1995, De Groote P et al 1998). 
Although ventricular interdependence is always present, it is most apparent with 
changes in loading conditions, such as those seen with volume loading (Atherton et al. 
Lancet 1997). Thirty percent of our subjects had tricuspid regurgitation with moderate 
TR accounting for the highest proportion (18.2%). This was largely functional 
regurgitation (Stewart S et al 2008) linked to right ventricular dilatation, rather than any 
structural abnormalities on tricuspid valvular leaflets.  The prevalence of tricuspid 
regurgitation of 30% in our hypertensive heart failure subjects is much higher than that in 
the Heart of Soweto Study (Stewart S et al 2008). Furthermore, the worse right 
ventricular function in our subjects, as reflected by higher prevalence of tricuspid 
regurgitation, may reflect the late presentation of our subjects compared with Soweto, 
which may be attributed to less access to medical care by our subjects in Abuja 
compared to Soweto. 
Factors found in linear regression analysis to be associated with abnormal RV function 
are shown in table 4.13 and include dilated left atrium and left ventricle, increased LV 
mass, reduced LV systolic function, restrictive filling pattern and right ventricular systolic 
pressure. Dilated left ventricle has been previously shown to have an impact on right 
ventricular function as measured by TAPSE (Kjaergaard J et al 2007). Also, reduced left 
ventricular ejection fraction has been shown to have an impact on TAPSE, even in the 
setting of preserved right ventricular ejection fraction (Di Salvo TG et al 1995, Lopez-
Candales A, et al 2006). The effect of left ventricular ejection fraction on TAPSE has 
been attributed to ventricular interdependence (Di Salvo TG et al 1995, De Groote P, et 
al 1998). Similar to our findings, TAPSE has been found to be correlated to markers of 
diastolic dysfunction and right ventricular systolic pressure (Hines R et al 1986), also 
similar to previous studies, left ventricular end-diastolic diameter were not related to 
TAPSE (Kjaegaard J et al 2009).  Although there was no correlation between TAPSE 
and serum levels of ST2 and NT-pro BNP in our study, RVSP correlated well with both 
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serum ST2 and NT-pro BNP with correlation coefficient of 0.75 and 0.54 respectively 
and p-values of < 0.0001 respectively as shown in table 4.13. This is in keeping with a 
previous report on heart failure subjects with coronary heart disease as the aetiological 
factor (Ravi V et al 2009). 
At presentation, most of our subjects had chamber dilatation (especially left-sided 
chambers), which might account for the significant systolic function, with an average left 
ventricular ejection fraction of 38%. The mean low systolic function in our hypertensive 
cohort with heart failure is as not surprising systolic function dysfunction has been 
previously linked to hypertension in the black population. There was also significant and 
diastolic dysfunction with an average transmitral E/A ratio of 2.2, suggestive of a 
restrictive filling pattern.  Our male subjects had significantly greater chamber dilatation 
than women. This has already been reported in the Heart of Soweto study (Stewart S et 
al 2008) and, possibly, linked to genetic factors and higher alcohol consumption in men, 
compared to women.  
Less than 25% of our subjects had heart failure with preserved ejection fraction (LVEF > 
50%), lower than what is reported in the western population (30-40%). However, we 
found HFPEF to be more common in women (55.4%), compared to men (44.6%), which 
is similar to the Western population (Smith GL et al 2003, Vasan RS et al 1999).  
 
LIMITATIONS 
This thesis has a number of limitations. We could have tested for other biomarkers like 
Cardiotrophin-1 and metalloproteinase but were limited by funds. Also, since the 
diagnosis of ischaemic heart disease was made clinically using history, 
electrocardiography and cardiac troponin I with no myocardial perfusion imaging and 
coronary angiography being performed, it is very possible that subtle coronary artery 
disease might have been omitted. However, with the low prevalence of clinical 
myocardial infarction and the high cost of myocardial perfusion and coronary 
imaging in this environment we did not think it was justifiable for these subjects 
to have these investigations. 
  In addition, the present thesis is limited by the number of subjects and therefore, the 
relationship between plasma NT-pro BNP and soluble ST2 should be largely viewed as 
hypothesis-generating for studies in population group. This report involved a relatively 
small sample sizes and also groups with unequal numbers. In order to assess the 
predictive power of these markers and generate more accurate conclusions as regards 
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how they relate to the different spectrum of hypertensive heart disease, a larger 
prospective study involving serial biomarker assessment in a large number of subjects 
should be carried out.   
In spite of these limitations enumerated above, the careful and extensive phenotyping of 
our study subjects as regards clinical, echocardiographic and biochemical parameters is 













 Figure 5.1: Meta-analysis of the efficacy of different antihypertensive drug 
classes in decreasing left ventricular mass ٭=P<0.05 versus β-blocker, ϯ= P<0.01 












CONCLUSION AND PERSPECTIVES 
This PhD thesis has contributed considerably in showing that soluble ST2 has a high 
sensitivity and specificity in detecting and differentiating the various spectrum of 
ventricular remodelling in hypertensive heart disease. We have also shown that soluble 
ST2 does not only complement the role of NT-pro BNP in differentiating the different 
spectrum of hypertension but is a better biomarker than NT-pro BNP in this regard 
(Figure 6.1).  Our findings will therefore assist in identifying patients at higher risk of 
evolution to heart failure and thereby halting this process by initiating appropriate 
medications which will include the rennin-angiotensin-aldosterone blockers, and close 
follow-up and monitoring of such patients. As it is well known that LVH if untreated often 
progresses to heart failure in more than 50% of cases (Drazner et al 2005), early 
diagnosis of hypertensive LVH and appropriate treatment using medications like 
angiotensin converting enzyme inhibitors and angiotensin receptor blockers has the 
potential to reduce and delay the onset of hypertensive heart failure. This will therefore 
in no small reduce the burden of hypertensive heart failure which is the commonest form 
of heart failure in our environment (Damasceno et l 2012). 
Soluble ST2 concentration was also found not only to be higher in hypertensive subjects 
with left ventricular hypertrophy when compared with those without hypertrophy, but was 
further highest in concentric hypertrophy compared to other geometric patterns. This is 
also very important finding as the extent of the risk posed by left ventricular hypertrophy 
in hypertension also depends on the particular geometric pattern, with concentric LVH 
having a higher prevalence of associated cardiovascular complications or death than 
those with other geometric patterns. In addition, subjects with concentric LVH also have 
also been found to have the most advanced extra-cardiac target-organ damage 
compared to other geometric pattern.  As increasing evidence has demonstrated the 
central importance of left ventricular mass and geometry especially concentric 
hypertrophy in the pathophysiology and prognosis of hypertension, early identification of 
these measures of preclinical disease as shown in our study with soluble ST2 can aid 
clinical decision- making by separating patients into those with a high or a relatively low 
risk with the need for pharmacological treatment with medications containing the rennin-




Apart from the association of soluble ST2 with left-sided chamber sizes, the 
concentration of soluble ST2 also correlated well with right atrial area and right 
ventricular diameter much more than NT-pro BNP. Therefore, soluble ST2 and NT-pro 
BNP are not only markers of left cardiac chamber remodelling but may have place on 
the remodelling of the right cardiac chambers. And this may therefore be a pointer to the 
importance of right ventricular remodelling in hypertensive heart disease which has been 
previously neglected. In addition, we found that a large proportion of our subjects 
(42.9%) with hypertensive heart failure of the showing further that right ventricular 
function assessment is important in the assessment of the hypertensive subject with 
heart failure.  
 
Also, this thesis contributes to our knowledge of the role of NT-pro BNP in cardiac 
remodelling in hypertension in African subjects. Most especially, this is one of the first 
works that has shown that the role of NT-pro BNP in hypertension although weakly, 
transcends left ventricular remodelling to the remodelling of the right ventricle. 
Furthermore, the present thesis has shown that the, soluble ST2 is not only a marker in 
the diagnosis of ischaemic heart disease, but it is very important in the diagnosis of the 
various spectrum of hypertensive heart disease and in identifying hypertensive 
concentric hypertrophy. Soluble ST2 may therefore be a new method of studying 
myocardial geometry in not only ischemic heart disease but in hypertension, and may be 
a future biomarker in assessing the full impact of hypertension on the myocardium. This 
thesis has therefore created the need for soluble ST2 to be tested in a larger prospective 
study involving a larger number of patient and also a longitudinal study to investigate if 
its role extends beyond diagnosis to therapeutic monitoring with the ultimate aim of 
developing a point-of-care which will eventually guide in the choice of medications like 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-1-
selective agents and long-acting calcium antagonists, and also lifestyle changes which 
have been proven to regress LVH. For example, the beta-1-selective blockers, 
Bisoprolol and Atenolol were shown to cause regression of LVH in hypertensive subjects 
(Gosse P et al 1990, Margaroli et al 1985), just like Metoprolol (Cifkova R, et al 1987). 
The long acting calcium channel blocker was also found to cause LVH regression in 
hypertensive diabetic subjects (Nalbantgil et al 1996). In addition, numerous 
investigations have demonstrated the beneficial effect of angiotensin converting enzyme 
inhibitors on LVH regression such as Captopril (Lombardoi M et al1983), Fosinopril 
(Cheung BMY et al 1999) and lisinopril (Shimamoto H et al 1996, Rizzoni et al 
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1997).Furthermore, several angiotensin receptor blockers like Losartan (Cuspidi et al 
1998) and Candersartan (Mitsunami K et al 1998) have been shown to cause regression 
of LVH in hypertensive patients. Apart from the use of therapeutic agents, the TOMHS-
Study showed that appropriate lifestyle changes in antihypertensive treatment causes 
significant regression of LVH in patients with mild hypertension (Liebson et al 1995). 
Another possible area of the use of this novel biomarker is the monitoring of the 
effectiveness of such therapeutic agents like angiotensin converting enzyme 
inhibitors and angiotensin receptor blockers in the regression of LVH in 
hypertensive heart disease. To determine this, a follow up study of a cohort of 
hypertensive disease subjects will be needed. 
However, for such an assay to be used as point of care it must be cheaper and easier to 
perform compared to conventional electrocardiography and echocardiography. For 
example, the present cost of assaying for NT-Pro BNP in private health facilities in 
Abuja, Nigeria which is three to four times above that of electrocardiography and 
comparable with that of echocardiography restricts its use in clinical practice.  
Also of note, the present thesis is one of the first studies in sub-Saharan Africa to show 
that a large proportion of our hypertensive heart failure subjects have right ventricular 
systolic dysfunction on presentation, further strengthening the need for the full 
assessment of right ventricular systolic to be part of echocardiography protocol  in our 




















Figure 6.1: Schematic diagram comparing soluble ST2 and NT-Pro BNP as 
Biomarkers in Hypertensive Heart Disease. HT= Hypertension without LVH and 
heart failure, HTLVH= Hypertension with LVH but no heart failure, 
HHF=Hypertensive Heart Failure.  
=Better than. 
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Figure 6.1 Comparison of different markers for ventricular remodelling in hypertensive 
patients. Our study demonstrates that, unlike NT-pro BNP, soluble ST2 differentiates the 
whole spectrum of hypertensive heart disease.  The relative lower cost, the absence of 
special training and the better accessibility of ST2 analysis compared to 
echocardiography suggests that ST2 analysis should be implemented as a “routine test” 
in patients with hypertensive disease, especially in countries where access to 
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